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INTRODUCTION 
Structure and Lytic Cycle. Cytomegalovirus (CMV) is an enveloped 
double-stranded DNA virus belonging to the family Herpesvirideae. Other 
human viruses which are classified in this family include Epstein-Barr 
virus (EBV), herpes simplex types 1 and 2 (HSV-1, HSV-2) and varicella-
zoster (VZV). The growth characteristics of these viruses in tissue 
culture differ with respect to permissive cell type, length of replica-
tion cycle and extracellular viral titer (20). HSV types 1 and 2 grow 
in a variety of mannnalian cells with a short replication cycle resulting 
in release of the virions into the extracellular fluid. By comparison 
CMV is highly species-specific. Wild-type human CMV (HCMV) replicates 
very slowly only in human fibroblasts with little or no release of virus 
into the tissue culture fluid. Repeated passage of HCMV isolates in 
culture may eventually result in measurable viral titer in the extra-
cellular fluid. The titer, however, varies with the particular strain. 
The complete virion of CMV is composed of a double-stranded linear 
DNA-containing core, an icosahedral capsid and an envelope (123). Elec-
tron micrographs, however, have demonstrated the presence of many in-
complete viral particles. In general four morphological types are pre-
sent: naked empty cores, naked "full" cores, enveloped empty cores and 
enveloped "full" cores corresponding to intact virions (37, 44, 144). An-
other characteristic form found in CMV-infected cells is the "dense 
body", which appears to be excess viral structural proteins with an en-
velope. The dense bodies carry CMV-specific antigens but have no detec-
1 
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table DNA (56,110,124). 
Electron microscopy has also been used to compare the replication 
steps of RSV and CMV. Both viruses enter cells by phagocytosis or 
fusion with the plasma membrane. Both rapidly traverse the cytoplasm to 
the perinuclear area, but CMV nucleocapsids appear to acquire a fine 
fibrillar coat in the cytoplasm and are subsequently disassembled much 
more slowly than RSV nucleocapsids (4, 113). Adsorption and penetration, 
therefore occur equally rapidly in both HSV and CMV infections, but sub-
sequent steps in viral replication are much slower for CMV than for RSV 
(20, 137). 
Epidemiology. The slow rate of CMV replication and the highly 
cell-associated nature of the virus have presented problems for diag-
nosing human infections. CMV is an ubiquitous virus as demonstrated by 
the high percentage of seropositive persons in various social groups. 
Detectable antibody titers have been found in 53% of children in a day 
care center (90), 12% of a group of pregnant women (103), 80% of the 
general Swedish population (139) and 94% of homosexual men (28). Most 
infections are asymptomatic, but serious complications may occur follow-
ing prenatal, perinatal or iatrogenically-induced exposure. This last 
group of patients includes organ transplant and transfusion recipients 
(19,46,70,87,96,104). 
Recently CMV has been linked with the acquired immune-deficiency 
syndrome (AIDS) observed mainly among drug users, male homosexuals,· 
Haitians and hemophiliacs (24,28,42,82,89,132). Many of these patients 
have detectable CMV antibody titers, and often the virus can be isolated 
from clinical specimens (48,42) in some cases in the absence of a rising 
antibody titer to CMV (29). Other opportunistic infections such as 
3 
Pneumocystis carinii and Candida albicans are also frequently present, 
thus the exact role of CMV in this new disease has not been established. 
In a recent study disseminated CMV infection was found at autopsy in 14 
out of 15 AIDS patients. This suggests that CMV viremia may be in many 
cases the immediate cause of death (79), although CMV is probably not 
the agent which produces the initial inununodeficiency (38). 
Congenital infection depending on the severity may result in a 
range of symptoms from death to persistent viruria. The central nervous 
system (CNS) is most often affected. Confirmation of congenital infec-
tion requires isolation of virus from specimens such as urine taken 
during the first week of life (27,119). The source of the virus appears 
to be predominately a reactivation of maternal infection, although occa-
sionally primary maternal disease occurs during pregnancy (121,139). 
The severity of symptoms is greatest with primary maternal infection, 
but factors such as gestational age at the time of infection and the 
innnune response of the fetus may also contribute to the clinical out-
come (10,91,92,120,121). 
Perinatal infection is also usually maternal in origin, but noso-
comial sources may produce disease in some cases (51,117,139). The 
maternal infection is again generally a reactivation of latent virus (61) 
and is passed to the infant through the genital tract or in breast milk 
(62,90,103). In contrast to congenital infection, the CNS is not the 
most frequently affected organ. Instead perinatal disease may be de-
tected in the liver, spleen, kidneys and hematopoietic tissues. In some 
cases the children have neurologic sequelae even though they are ini-
tially asymptomatic. Slow psychomotor development and loss of hearing 
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may become apparent at a later age (139). Again as with congenital dis-
ease the severity of perinatal CMV infection is greater in association 
with primary maternal infection (121). 
In adults CMV is often isolated from multiple transfusion recip-
ients and renal, cardiac, or bone marrow transplant patients. Viruria, 
cytomegalic inclusion pneumonia and heterophile-negative mononucleosis 
are the most common CMV-related diseases found in these patients (25,70, 
95,139). Whether the disease represents reactivation of latent virus or 
exogenous donor infection has not been completely determined. CMV has 
been recovered from the buffy coat of donor blood (25,61); multiply-
transfused patients show a higher rate of seroconversion, and the timing 
of the rise in antibody titer is not characteristic of an anamnestic 
response (96). It would appear, therefore, that donor blood can be a 
source for CMV transmission. The possibility of reactivation of latent 
infection cannot be ruled out, however, since allogeneic stimulation of 
infected lymphocytes has been observed in mice (70,87). In addition, 
molecular analysis of CMV strains from a group of blood donors and their 
recipients has demonstrated a lack of relatedness between the correspond-
ing viral isolates (61). 
Organ transplant recipients appear to be very susceptible to CMV 
infection. In the majority of cases the source of the virus is probably 
a reactivation of latent host infection. In one study of renal trans-
plant recipients all patients who developed active CMV infections had 
detectable CMV antibody before receiving renal allografts (106). The 
CMV viremia was associated with graft dysfunction. 
In a series of cardiac transplant patients (95) the donors were 
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demonstrated to be the source of CMV when the recipients were seronega-
tive for the virus. These recipients had primary CMV infection from a 
reactivation of latent virus in donor tissue or contaminating blood. 
The recipients who were seropositive for CMV before transplantation and 
who subsequently developed CMV viremia, most likely had a reactivation 
of latent host virus, although reinfection from a nosocomial source has 
been reported (133). 
CMV infection in transplant or transfusion recipients, therefore, 
often occurs in spite of measurable serum antibodies (30,46,54,95,96, 
104), and the outcome may depend on the cellular immune response, which 
is usually depressed in the presence of CMV (12,32,99,100,108,136). In-
version of the T-cell helper/inducer ratio in patients following trans-
plantation may be predictive of the risk of developing CMV infection 
(111). Active CMV infection may cause immunosuppression (32,102,108). 
Therefore, efforts to determine the exact pathogenesis of CMV in trans-
plant recipients have not produced conclusive answers. 
Latency and Oncogenicity. Since latency of CMV appears to play a 
significant role in the pathogenesis of the virus for these immunocom-
promised patients, there have been a number of studies to determine the 
site of the latent infection. Polymorphonuclear and adherent mononu-
clear leukocytes seem to be the most likely sources of inactive virus 
(25,30,31,67,68,107), although cultivation of cells from other sources 
has occasionally resulted in productive viral infection (143) or detect-
able CMV antigens (101). Factors which may trigger activation of the 
virus include another acute infection (69), host immunosuppression (70) 
or host response to allogeneic cells (87). 
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In addition to its ability to produce latent infection, CMV may 
abortively infect nonpermissive cells (9,37,39,101). Abortive infection 
may result in stimulation of cellular DNA and RNA synthesis (2,22,37). 
Early viral antigens are expressed, but viral DNA cannot be detected 
(23,75). Similar abortive infections are characteristic of oncogenic 
DNA viruses such as SV-40, polyoma and adenovirus (37). 
There is evidence that CMV also is potentially oncogenic (1,2). 
Albrecht and Rapp (1) infected nonpermissive hamster embryo fibroblasts 
with a human CMV strain and obtained a cell line which produced tumors 
in weanling hamsters. After animal passage, however, no virus could be 
rescued, although the tumor-bearing animals had antibodies to CMV anti-
gens. Another group of investigators (101) grew a cell line from in 
vivo CMV-infected human prostate cells to passage levels well above nor-
mal. Again no virus could be rescued, the karyotype was diploid and no 
tumors were produced in nude mice. The cells were, however, no longer 
contact-inhibited, and CMV-specific antigens were expressed. Getler et 
al. (39) reported transformation of human embryonic lung cells infected 
at a low multiplicity of infection (MOI) with CMV. Their cell line in-
duced tumors in nude mice, expressed CMV-specific membrane antigens and 
underwent uncontrolled nuclear divisions in the presence of cytochalasin 
B. 
The outcome of CMV infection, therefore, may be influenced-by the 
type and species of cell, the physiological state of the cell (19,22) 
and the temporal expression of the viral genome (20,125,137,138). Three 
groups of virus-specific proteins have been described based on their 
order of appearance and expression in the infected cell. Immediate early 
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polypeptides (IEP) are produced in lytically-infected cells after treat-
ment with protein synthesis inhibitors or in abortively-infected cells 
(45,64,127). There is a switch from IEP to early proteins (EP) within 
two hours postinfection in lytically-infected cells. Early proteins are 
also expressed in the presence of viral DNA inhibitors and in latently-
infected cells (6,44). Late proteins (LP) require viral DNA synthesis 
for expression and are, therefore, not produced in nonpermissive, abort-
ively or latently-infected cells (6,43,83). Such temporal control of 
genome expression is typical of DNA viruses. The regulatory proteins 
involved may be responsible for the prolongation of the CMV lytic cycle 
and for the determination of latency or persistence in non-lytic in-
fections (137). 
Molecular Characteristics of CMV DNA. Molecular analysis of the 
DNA of different HCMV isolates has been used to study the different types 
of viral infection. It is now known that the size of the infectious 
HCMV genome is approximately 150 x 106 daltons with some variation among 
individual strains (19,40,126). Early studies had reported that the CMV 
genome was 100 x 106 daltons, which is the size of RSV DNA. These re-
ports also mentioned a less abundant class of molecules of 150 x 106 
daltons (19,57,72,76). Stinski et al. (126) demonstrated that a low MOI 
resulted in production of the majority of viral DNA molecules of the 
larger size class. 6 Thus, the 100 x 10 dalton species represented de-
fective genomes, which appeared in larger numbers when the MOI was 
greater than 1. 
The structure of the CMV genome is similar to that of the herpes 
simplex viruses in spite of the difference in size. There is a long 
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unique sequence (U1) bounded by inverted repeats (II),) and a shorter 
unique sequence (US) also bounded by a different set of inverted repeats 
(IRS) (Fig. 1). The presence of submolar fragments in restriction endo-
nuclease digests of the viral DNA supports a model in which there are 
four possible genome arrangements. Inversion of each unique sequence 
and its repeats relative to the other produces the four structures, which 
are present in approximately equal amounts in infected cells (15,49,72, 
141). 
Although HSV 1 and 2 and CMV have structurally similar genomes 
they appear to lack homology. Renaturation kinetics by DNA-DNA hybrid-
ization has demonstrated less than 5% homology between HCMV strains and 
HSV. Cytomegalovirus also does not share homology with other herpes 
viruses such as EBV (58). 
Restriction endonuclease cleavage patterns and nucleic acid hy-
bridization techniques have been used to determine strain variation of 
CMV (61,115,128). Strains of CMV from the same species show approx-
imately 80% or greater homology of the DNA genome (59,97), and restric-
tion endonuclease site polymorphism has been used to determine the epi-
demiology of exogenous and endogenous infections (26,62,84). Comparisons 
of CMV strains using several restriction endonucleases have provided 
strain-specific "fingerprints". Huang et al. (62) studied a group of 
women and their infants who had evidence of CMV infection within .the 
first year of life. The pattern of DNA restriction fragments of mother 
and offspring were either identical or showed very little variation. 
Repeat isolates from some of the same patients over a period of as long 
as nine years showed stability of the viral genome responsible for the 
9 
Figure 1. The structure of the genome of HCMV. The four arrange-
ments are generated by the ability of each unique se-
quence and its associated repeats to invert in relation-
ship to each other. 
I~ = long inverted repeat sequence 
IRS = short inverted repeat sequence 
UL = long unique sequence 
us = short unique sequence 
~Cl) 
H 
,0 
(.) (.) 
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initial infection. Only CMV isolates from the same or related persons 
were essentially identical. Unrelated controls carried heterogeneous 
strains of CMV. In spite of the apparent strain stability, however, 
there is as yet no classification of CMV similar to that of HSV, which 
can be separated into two types by both antigenic and molecular criteria 
(71,123). 
Several groups of investigators have mapped and cloned the genome 
of the common laboratory strains of HCMV such as Davis (21), Towne (74) 
and AD169 (49,130). Specific cloned fragments of the DNA have been used 
to look for homologous sequences in cellular DNA and other herpesvi-
ruses. From these studies it has been determined that there are regions 
of homology with cellular DNA, and that certain cloned fragments are 
able to transform cells. 
Nelson et al. (85) identified a 2.9 kilobase (kb) region of the 
AD169 genome, which was capable of transforming NIH 3T3 cells. This re-
gion is about 20 kb from the left end of the UL sequence (Fig. 2). The 
cells transfected with plasmids containing this part of the genome dis-
played anchorage independence and tumorigenicity in nude mice. The 
transcription of this region corresponds to an area of IEP messenger RNA, 
although no translation product has been isolated. Sequencing data in-
dicate that there is no viral protein product from this region, there-
fore, the mechanism of transformation is not known (86). 
A second transforming region of the CMV genome has been reported 
by Clanton et a1.· (14). This region shows homology to one of the trans-
forming regions of HSV-2, when hybridization is performed under non-
stringent conditions. The cloned fragment from the Towne strain of CMV 
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Figure 2. Restriction enzyme map of CMV AD169 genome. 
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hybridized to a unique fragment of AD169, but this was also different 
from the transforming fragment described by Nelson (85). The Towne frag-
ment was able to transform Syrian hamster embryo cells. Immortal lines 
were produced which grew in 2% serum and displayed anchorage indepen-
dence. There appear, therefore, to be two separate transforming re-
gions in the HCMV genome both of which show some homology to transfor-
ming regions previously found in HSV-2 (14). 
Spector and Vacquier (116) described nucleotide sequences related 
to the transforming gene (v-myc) of avian myelocytoma.tosis virus, which 
were present in the genome of AD169. There were several regions in the 
u1 segment and the IRS, which showed homology to the 5' end of the v-_!!!Y£. 
These regions, however, did not correspond to the transforming region 
identified by Nelson et al. (85). Since the v-myc sequence is homol-
ogous to cellular oncogenes (c-_!!!Y£), these authors postulate that there 
may be early activation of c-myc followed by activation of another set 
of genes to produce cell transformation. 
To investigate further the relationship of these transforming re-
gions with the known cellular and viral oncogenes (c-myc and v-myc), 
Gelman et al. (41) showed that myc-homologous sequences were present in 
subfragments of one of the Towne transforming fragments (14). These re-
gions of homology in the HCMV genome, however, corresponded only to the 
5' half of the c-myc and v-_!!!Y£ sequences. Whether or not the virus 
acquired these sequences by recombination with human DNA cannot yet be 
determined. 
There are sequences found in the intermediate repetitive class of 
mammalian cellular DNA, which hybridize weakly to CMV Towne DNA frag-
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ments containing the junction between the long and short segments and to 
fragments carrying the termini of the long inverted repeat (93). Similar 
cell-virus DNA homology has been demonstrated for HSV 1 and 2 (93,98). 
The inverted repeats of HSV 1 and 2 also show the strongest hybridiza-
tion with cellular DNA (93). 
Taken together these studies of the CMV genome indicate that some 
homology exists between certain segments of the viral DNA and mannnalian 
cellular DNA. Some of these sequences may be responsible for cell trans-
formation, but what role they might play in lytic or latent CMV in-
fection is still unknown. 
Rapid Detection of CMV. The potentially severe consequences of 
CMV infection make rapid diagnosis desirable. Routine virus cultures of 
patient specimens for CMV of ten require two weeks or longer to produce 
visible cytopathic effect (CPE) (27). Serodiagnosis is the only cur-
rently available technique for detecting CMV infection in the absence of 
a positive virus culture (35,36,50,56,131). The two techniques which 
show the most promise for rapid viral identification are: 1) detection 
of early viral antigens with monoclonal antibodies, and 2) hybridiza-
tion of viral nucleic acids with labelled probes. 
Monoclonal antibodies specific for CMV-infected cells are avail-
able (47,73,94,135). Strain AD169 was used to produce the antibodies, 
but cross-reactivity with other strains of CMV from both laboratory and 
clinical sources demonstrated the potential for universal detection of 
CMV infections. Several of the antibodies reacted with early CMV gly-
coproteins (47,73), which could allow rapid detection of the virus in 
cell culture. An antibody reacting with a late glycoprotein (47) also 
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was able to detect virus directly in clinical specimens. These reports 
indicate that it may be possible to develop monoclonal antibodies for 
antigens present early in infection by all strains of HCMV. 
For this project the technique of nucleic acid hybridization has 
been chosen as a possible method for rapid detection of CMV. Since there 
is such a large percentage of DNA homology among CMV strains (58,142) it 
should be possible to develop a probe which will hybridize to all HCMV. 
In addition the low amount of homology between the genomes of CMV and 
the other herpes viruses such as HSV-1, HSV-2 and EBV indicates that 
hybridization could be expected to be specific for CMV. 
The goal of this project has been to select a cloned fragment of 
the CMV genome of strain AD169 (109) which is common to all strains of 
the virus but unique to CMV. Such a fragment could then be used as a 
labelled probe for detection of CMV at an early stage of infection in 
tissue culture or directly in clinical specimens. The large size of the 
viral DNA (150 x 106 daltons) precludes the cloning of the entire genome, 
thus an appropriate fragment needs to be selected from among those pro-
duced by restriction endonuclease digestion of the viral DNA. 
Two potential problems must be considered in the selection of a 
cloned fragment. First, in spite of the large degree of homology among 
isolates of CMV, there is still significant lack of homology between par-
ticular segments of the genomes of individual strains. La Femina et al. 
(74) showed that CMV Davis and AD169 have 2000-4000 base pair deletions 
relative to CMV Towne. The deletions appear to occur at the extreme in-
ternal segments of the II),· The rest of the genomes of CMV Towne and 
Davis show a high degree of homology. Westrate et al. (142) reported a 
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similar study comparing CMV AD169 and CMV SG. The majority of the viral 
DNA of the two strains cross-hybridized, but there were two areas which 
did not. These sequences were in the repeats and at the left end of the 
U segment. In selecting a fragment for a CMV cross-reactive probe, L 
therefore, it would be best to avoid fragments which may not contain se-
quences capable of hybridizing to all samples of HCMV DNA. 
The second problem is that of homology between portions of the CMV 
genome and mammalian cellular DNA sequences. The segments of the CMV 
DNA which are homologous to portions of the v-.!!!Y.£_ and c-.!!!Y.£_ genes (14, 
41,85,116) and those which hybridize to intermediate repetitive cell DNA 
sequences (93,98) could lead to an undesirable background level of hy-
bridization of the probe in tissue culture. Restriction endonuclease 
maps are available for determining which fragments may contain sequences 
that might increase the level of background hybridization (21,49,75,88). 
To develop a probe for the purposes of this project CMV AD169 DNA 
was isolated from extracellular virus in tissue culture fluid. The DNA 
was digested with BarnHI and fragments were inserted into pBR322. The 
plasmids were transformed into ]_. coli SF8 and screened for tetracycline 
sensitivity. Recombinant clones were analyzed for large inserts. An 
insert co-migrating with the CMV Bamlll A/B fragments was selected and 
subsequently identified as the 15 kb B fragment. The recombinant plasmid 
was radiolabelled with 32P-deoxycytidine by nick translation and assayed 
for cross-reactivity with restriction endonuclease digests of EBV; HSV-1 
and HSV-2 (80,114). The specificity of the labelled probe was demon-
strated by hybridization to cells in tissue culture infected with differ-
ent CMV strains from clinical sources. Sensitivity of the radiolabelled 
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probe was determined by hybridization to dilutions of CMV AD169 DNA and 
cell-free virus stocks. Patient urine specimens submitted for CMV cul-
ture were used to demonstrate the potential clinical application of the 
probe for CMV detection or identification. 
A final phase of this project has been a comparison of the sensi-
tivity of the probe labelled with 32P with the same probe labelled with 
biotin. There are two potential advantages of a biotin-labelled probe 
for clinical laboratory application: 1) elimination of the need for a 
radioactive isotope and 2) stability of the probe activity. 
The Enzo-Biochem conunercial nick translation kit was used to in-
corporate biotinylated deoxyuridine into the probe. The detection sys-
tem is based on the strong binding of the protein avidin to biotin. 
Avidin is tagged with horseradish peroxidase and addition of the enzyme 
substrate produces a colored product at the site of binding to the 
probe (4,8,80). 
The biotin-labelled probe was hybridized to CMV AD169 DNA, stock 
virus dilutions and cells infected with different CMV strains. The re-
sults of these hybridizations were compared to the parallel results ob-
tained under the same conditions with the radiolabelled probe. 
MATERIALS AND METHODS 
Virus. CMV strain AD169 (109) was obtained from Dr. Marc Beem at 
the University of Chicago. A second sample of CMV AD169 was kindly 
donated by Dr. Robert Betts at the University of Rochester. 
Virus stocks were frozen and maintained at -70°c in medium con-
taining 10% dimethylsufoxide (DMSO) and 10% fetal calf serum (FCS). 
0 When needed the stock virus was rapidly thawed in a 35 C incubator and 
diluted appropriately in Earles balanced salt solution (EBSS). Samples 
of CMV isolated from patient specimens received by the clinical micro-
biology laboratory at Loyola University Medical Center were also col-
lected, passaged and stored. 
Cells. Rl.UI!an foreskin fibroblasts (HFS HR218 passage 19) were 
' purchased from HEM Research, Rockville, MD for large-scale growth of the 
virus. Additional HFS (MRHF passage 22-23) were purchased from M.A. 
Bioproducts, Walkersville, MD. These cells were routinely passaged 1:2 
up to a maximum passage of 29. In some experiments human embryonic 
lung (REL MRC-5) cells also from M.A. Bioproducts or WI-38 cells (Flow 
Laboratories, McLean, VA) were used. 
For storage cells were frozen and maintained under liquid nitrogen 
in medium containing 10% DMSO and 10% FCS. When needed the cells were 
quickly thawed in a 35°c incubator, placed in 10 ml of EBSS and centri-
fuged at 1500 rpm in a Sorvall H4000 rotor at 4°c for 15 min. The su-
pernatant was discarded and the cell pellet was resuspended in 5 ml of 
growth medium (see below). The suspension was then plated in the appro-
priate number of flasks or plates for a 1:2 split. 
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Confluent monolayers were detached with filtered (0.22 µm Milli-
pore) 0.25% trypsin. Generally incubation at 35°c for 10 min was suffi-
cient for the trypsin to remove the cells; however, monolayers which had 
been under maintenance medium (see below) at confluency for several days 
required longer incubation times. Detached cells, diluted 1:4 in trypan 
blue, were counted with a hemocytometer. 
Tissue Culture Media. Cells were grown in Eagle's minimum essen-
tial medium (MEM) supplemented with 10% FCS, 7.5% NaHC03, (to adjust pH 
to 7.2), L-glutamine (1 mM), HEPES buffer (20 mM), gentamicin (50 µg/ml) 
and _amphotericin B (2.5 µg/ml). This is referred to as growth medium. 
Maintenance medium was Eagle's MEM with the same supplements except only 
1% FCS and no HEPES. Earles balanced salt solution was used for washing 
cell monolayers and for making serial dilutions as virus. The overlay 
for plaque assays consisted of equal parts of 0.6% agarose and double 
strength maintenance medium (140). 
Bacteriological Media. L broth for growth of !· coli consisted of 
tryptone (lOg), yeast extract (5g) and NaCl (5g) in a total volume of 
1 liter. The pH was adjusted to 7.1-7.4 with NaOH (80). 
For large-scale isolation of plasmid DNA the bacteria were grown 
in A.B. minimal medium consisting of K2HPo4 (3g/l), NH4Cl (lg/l), 
Mgso4 .7H20 (0.3 g/l), KCl (0.15 g/l), CaC12 .2H2o (0.0~ g/l), FeS04.7H20 
(2.5 mg/l), glucose (5·g/l), Casamino acids (0.5%), L-tryptophan 
(25 µg/ml) and thiamine (5 µg/l) (11). 
For isolation and maintenance of recombinant clones nutrient agar 
plates (1.5% agar, 0.8% BBL or Difeo nutrient broth base) were used. The 
medium was supplemented with 100 µg/ml ampicillin or 10 µg/ml tetra-
cycline. 
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Reagents and Chemicals. The following is a list of sources for 
the conunonly used reagents and chemicals: FCS and amphotericin B (Fungi-
zone) from Gibco, Grand Island, NY; EBSS, Eagle's MEM, L-glutamine, 
NaHC03, HEPES buffer and trypsin from Flow Laboratories, McLean, VA; 
3 h ·d· d 32P d ·d· f 1 d 1 H-t ynu. ine an - eoxycyti ine rom New Eng an Nuc ear; gentamicin 
(Garamycin) from M.A. Bioproducts; CsCl from Harshaw Chemical, Solon, OH; 
Pronase B from Calbiochem-Behring, LaJolla, CA; Sarkosyl, sodium dodecyl 
sulfate (SDS), Trizma base, disodium EDTA, bovine serum albumin (BSA), 
dithiothreitol (DTT), calf thymus DNA, lysozyme and RNase A from Sigma; 
restriction endonucleases BamHI, HindIII, Pstl, EcoRI and _!!g!II from 
BRL, Gaithersburg, MD; boric acid, sodium citrate, sodium chloride, for-
mamide from Mallinkrodt, St. Louis, MO; polyvinylpyrollidone (PVP), 
ficoll 400, dextran sulfate and Sephadex G-50 from Pharmacia, Uppsala, 
Sweden. 
Plaque Assay. The method of Wentworth and French (140) was mod-
ified for titering and plaque purifying the virus. HFS cells were prop-
agated in growth medium in 24-well (diameter 16 mm) tissue culture 
plates (Falcon 3047) until just subconfluent (at least 2-3 days) (18). 
Virus dilutions from 10-l to 10-6 were made in EBSS. The growth medium 
was removed from each well and replaced with 0.1 ml of viral inoculum. 
Final viral dilutions were 10-2 to 10- 7• The virus was allowed to ad-
0 
sorb for 2 h at 35 C. The excess liquid was removed at the end of the 
adsorption period and replaced with an overlay of equal parts 0.6% 
agarose and double strength maintenance medium. Seven days later a 
second overlay was poured on top of the first. Plates could then be 
held for as long as 4-6 weeks without drying out. 
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Plaques were counted in wells containing no more than 10-15 well-
isolated plaques. The titer in plaque-forming units (pfu) was calcu-
lated according to the dilution. Wells containing no more than three 
well-isolated plaques were selected for plaque purification. A capil-
lary pipette was used to withdraw medium overlying well-developed 
plaques. 2 This inoculum was then placed on HFS cell monolayers in 25 cm 
flasks (Corning) for further culture. 
Passage of Stock Virus. Maintenance medium was changed every 5-7 
days until CPE reached 80-90%. From 3-4 days after 100% CPE was evident 
a 10-5 dilution of the extracellular fluid was made in EBSS. A 0.1 ml 
sample of the dilution was used to inoculate monolayers in 25 cm2 tis-
sue culture flasks. The MO! usually was low enough to maintain high-
titer virus (126). 
Electron Microscopy. Electron microscopy was performed by Dr. 
Raoul Fresco, at the Loyola University Medical Center, on a preparation 
of cells infected with 2 different samples of strain AD169. The first 
was a three-times plaque purified sample from the strain obtained from 
Dr. Marc Beem. The other was a one-time plaque purified sample of the 
strain supplied by Dr. Robert Betts. 
Large-Scale Growth of Plaque-Purified Stock Virus. In earlier ex-
periments 24 tissue culture flasks (150 cm2) of HFS cell monolayers at 
passage 25-27 were inoculated with 1 ml each of a 1:1,000 dilution of 
virus stock supernatant. The MO! was between 0.01 and 0.001. The virus 
was allowed to adsorb for 2 h and then 35 ml of maintenance medium was 
placed in each flask. 
. 3 
After 7-8 days each flask was labelled with H-
thymidine (3 µCi/ml). Extracellular virus was harvested at 13-15 days 
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post-infection, which was 3-4 days· after 100% CPE was reached in all 
flasks. 
In later experiments to increase the yield of virus, the cells 
2 
were initially propagated in tissue culture flasks (150 cm), and then 
2 
split to 10 roller bottles (850 cm). Each roller bottle was inoculated 
at subconfluency with 5 ml of a plaque-purified virus stock dilution. 
The MOI was between 0.1 and 0.01. Each roller bottle contained 125 ml 
of maintenance medium, which was changed at 7 days. The supernatant 
fluid was harvested 3 days after 100% CPE was observed. 
Purification of Virus From Supernatant Fluid. Several changes in 
this procedure were made from experiment to experiment to increase the 
yield of DNA. In earlier experiments the clarified supernatant fluid 
was centrifuged in a Beckman Ti 45 rotor at 25,000 rpm for 1 h through a 
20 ml cushion of 20% (w/v) D-sorbitol in 0.05 M Tris-hydrochloride (Tris-
HCl), pH 7.2, containing 0.001 M MgC12 and 100 µg bacitracin per ml (124, 
126). The pellets were resuspended by vortexing in a total of 1 ml Tris-
buffered saline (TBS 0.05 M Tris-HCl pH 7.2, 0.15 M NaCl) and combined. 
An additional 1 ml of TBS was used to sequentially rinse out the tubes. 
This was added to the combined pellet suspension. This suspension was 
layered onto a discontinuous sorbitol gradient (75%/48%/20% w/v). The 
0 gradient was centrifuged at 26,500 rpm at 20 C for 60 min in a Beckman 
SW 28 rotor (130). The visible band at the interface of 75%/48% sorbi-
tol was collected by side puncture. This material was diluted with TBS 
to 38 ml total volume and repelleted at 26,500 rpm at 20°c for 3 h in 
the SW 28 rotor. 
In later experiments 5% polyethylene glycol (PEG) 6000 (34,52) was 
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added to the supernatant fluid to precipitate the virus. Once the PEG 
0 
was dissolved the fluid was held at 4 C for 4 h and then centrifuged at 
7,000 rpm for 30 min at 4°c in a Beckman JA-14 rotor. The supernatant 
fluid was poured off and the viral pellet was resuspended in TBS. The 
virus suspension was placed on a discontinuous sorbitol gradient and pur-
ified as described above. 
The difficulty in resuspending PEG-precipitated virus prompted a 
further modification of the pelleting procedure (65,75). The clarified 
supernatant fluid was centrifuged for 90 min at 12,000 rpm in a Sorvall 
GSA rotor. The supernatant fluid was poured off and the remaining viral 
pellets were drained and resuspended in a total volume of 2 ml of buffer 
(0.4 M NaCl, 5 mM Tris-HCl pH 8.0, 100 mM EDTA). An additional 1 ml of 
buffer was used to wash the centrifuge bottles to collect any residual 
virus. 
Extraction of Viral DNA. In earlier experiments the final viral 
pellet was resuspended in 2 ml of buffer (O.l M NaCl, 0.01 M Tris-HCl, 
0.01 M EDTA pH 8.0) (130). SDS was added to a final concentration of 1% 
followed by RNase A (50 µg/ml) and pronase (1 mg/ml). This solution was 
incubated for 1 h at 37°C then extracted twice with 2 volumes phenol-
chlorofornrisoamyl alcohol (50:48:2) and once with 2 volumes of chloro-
fornrisoamyl alcohol (24:1). 
The treated lysate was placed in CsCl at a density of 1.72 ~/ml 
and centrifuged at 35,000 rpm at 20°c for 48 h in a Beckman type 50 rotor. 
The resulting gradient was fractionated; counts per minute (cpm) and re-
fractive index for each fraction were determined. Fractions showing peak 
radioactivity and corresponding to the density of CMV DNA (1.716 g/ml) 
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were pooled and dialyzed overnight with three changes of buffer (5 mM 
Tris-HCl, 1 mM EDTA pH 8.0). 
In later experiments a modification of the method of La Femina and 
Hayward (75) was used. RNase A (20 µg/ml) was added to the virus sus-
pension, which was then incubated at 37°c for 15 min. Sarkosyl (2%) and 
SDS (0.5%) were added, and the lysate was incubated at 37°c for 60 min. 
0 Pronase (1 mg/ml) was added and incubation at 37 C was continued for an 
additional 2 h. After extraction with phenol followed by chloroform/ 
isomyl alcohol (98:2), the aqueous layer was dialyzed as follows: 1 h 
against 2 L 10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 300 mM NaCl; over-
night against 2 L 10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0; 1 h in another 
2 L of the same buffer. 
In addition to the extractiop of DNA from extracellular virions, 
the remaining adherent cells were trypsinized, washed and pelleted. The 
cells were resuspended in a small volume of growth medium with 10% DMSO 
and frozen at -70°c for future extraction of intracellular virion DNA. 
Culture for Infectivity During Purification of Virus. Aliquots 
(O.l ml) from the original pellets, sorbitol gradient and repelleted 
virions were cultured to determine the amount of viral infectivity re-
maining at each step. A plaque assay was perfonned on each aliquot ac-
cording to the procedure outlined above (140). Titers expressed as pfu 
were determined after 21 days. 
Concentration of DNA. DNA samples were precipitated with 1/10 
volume 3 M potassium acetate plus 2 volumes of 95% ethanol. The samples 
were then placed on dry ice for 20 min and centrifuged in a Fisher model 
235 microfuge for 10 min. The supernatant was poured off and the DNA 
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precipitates were resuspended in a small volume of 10 mM Tris-HCl, 0.1 
mM EDTA pH 8.0. The DNA was stored at 4°c or frozen at -20°c. 
Isolation of Plasmid pBR322. One liter of L broth containing 5 µg/ 
ml tetracycline was inoculated with 10 ml of a 50 ml overnight precul-
ture of ~· coli strain RRl. The organism was grown with shaking in a 
35°c incubator (17) to a reading of 100 on a Klett-Summerson model 800-3 
colorimeter (No. 66 red filter). The bacteria were pelleted at 8,000 rpm 
for 5 min in a Sorvall GSA rotor. The supernatant was discarded, and 
the pellets were resuspended in ice-cold TE buffer (0.05 M Tris-HCl, 
0.05 M EDTA pH 8.0) and repelleted a second time. The pellets were then 
resuspended in 0.05 M Tris-HCl, 0.05 M EDTA pH 8.0 containing 15% su-
erase and 1 mg/ml lysozyme. This suspension was incubated at room tern-
perature for 10 min followed by the addition of 0.1% Triton X-100 in 
0.05 M Tris-HCl, 0.05 M EDTA pH 8.0. The lysate suspension was incu-
bated at 37°C for 30 min followed by short incubations at 55°c until 
lysis appeared complete. The lysates were centrifuged at 19,000 rpm for 
0 1 h at 4 C in a Sorvall SS-34 rotor. The non-viscous supernatant was 
removed and added to CsCl containing 0.1 mg/ml ethidium bromide for a 
3 final density of 1.59 g/cm • The sample was centrifuged at 38,000 rpm 
for 38 h in a Beckman VTi 50 rotor. 
The lower u-v fluorescent band in the gradient was collected. The 
ethidium bromide was removed from the collected material by repeated ex-
traction with isopropanol saturated with 20X SSC (lX SSC is 0.15 M NaCl, 
0.015 M trisodium citrate). The plasmid DNA sample was dialyzed over-
night against 10 mM Tris-HCl, 0.1 mM EDTA pH 8.0. The dialysate was pre-
cipitated with ethanol as outlined above. A 10 µl aliquot of the plasmid 
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.sample was subjected to agarose gel electrophoresis directly. Another 
aliquot of the sample was digested with restriction enzymes HindIII and 
HinfI, and the fragments were analyzed by agarose gel electrophoresis. 
Cloning Procedure. Approximately 1 µg of CMV DNA and 0.1 µg of 
the vector pBR322 were digested separately with BamHI. The digests were 
ethanol precipitated and resuspended in ligase buffer (60 mM Tris-HCl 
pH 8.0, 33 mM NaCl, 10 mM MgC12) containing ATP (0.5 mM) and DTT (5 mM). 
The ligation reaction mixture contained the precipitated digests of in-
sert (CMV) DNA and vector (pBR322) DNA at a concentration ratio of 10:1 
and 1 unit of T4 ligase. A control reaction mixture contained only di-
gested vector DNA with the same reagents. Both ligation and control 
mixtures were incubated overnight at 14°c. Following incubation the 
reaction mixtures were again precipitated with ethanol and resuspended 
in 60 µl of 0.1 M Tris-HCl pH 7.2. Aliquots of the concentrated mix-
tures were subjected to agarose gel electrophoresis for analysis. 
The streptomycin-resistant !· coli strain SF8 (genotype: hsdR , 
hsdM , recB, ~' lop-11 (ligase overproducer supE44), gal-96, leuB6, 
thi-1, thr; a gift from Dr. Masajasur Nomura, University of Wisconsin) 
was grown in an overnight preculture in 5 ml of L broth. A 0.2 ml sam-
ple of this preculture was added to 20 ml of L broth and grown to a 
Klett reading of 100. Transformation of the ligation reaction mixture, 
the control mixture and a standard pBR322 untreated control was per-
formed according to the method outlined in Davis et al. (17). The bac-
teria were sedimented by centrifugation at 5,000 rpm in a Sorvall SS-34 
rotor for 5 min at z0 c. The pelleted cells were resuspended in 10 ml 
0 
cold 50 mM CaC12 and incubated for 5-60 min at 0 C. The centrifugation 
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and resuspension steps were repeated in a 1 ml volume of CaC12 . The bac-
teria were then added in a 2:1 (v/v) ratio to the ligation mixture, the 
control mixture and the untreated pBR322 control and allowed to sit for 
10 min at o0 c. Each sample was incubated for 2 min at 37°c followed by 
10 min at 2S0 c. Ten volumes of L broth were added to each sample and 
they were again incubated at 37°C for 20 min. Dilutions of the cells 
from each sample were then plated out on nutrient agar plates containing 
ampicillin (100 µg/ml). Colonies which appeared on the plates from the 
ligation mixture transformation were numbered and picked to nutrient 
agar plates containing either ampicillin (100 µg/ml) or tetracycline 
(10 µg/ml). Colonies which were resistant to arnpicillin but sensitive 
to tetracycline were selected for further plasmid analysis. 
Rapid Technique for Plasmid Analysis. Recombinants from the clon-
ing procedure were analyzed by the method of Holmes and Quigley (SS). 
The organisms were grown overnight in l.S ml of L broth. Half of the 
cell suspension was transferred to a l.S ml microfuge tube and pelleted 
for 3 min at 4°c in a Fisher model 23S microfuge. The supernatant fluid 
was removed and the pellets were resuspended in 100 µl STET buffer (SO mM 
Tris-HCl pH 8.0, SO mM EDTA, 8% sucrose, S% Triton X-100). Eight micro-
liters of a 10 mg/ml solution of lysozyme was added and the tubes were 
placed in boiling water for 40 sec. The tubes were recentrifuged for 
0 0 10 min at 4 C and the supernatant was precipitated with ethanol at -18 C 
for S min. After another S min centrifugation the precipitates were re-
suspended in water at room temperature. Aliquots of these samples were 
then subjected directly to agarose gel electrophoresis. For restriction 
enzyme digestion analysis the samples were precipitated a second time 
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with ethanol and treated with RNase A for 30 min at 37°C. 
Agarose Gel Electrophoresis. Electrophoresis of undigested viral 
or plasmid DNA was performed on 0.7% horizontal agarose gels in a buffer 
(pH 8.0) containing 89 mM Trizma base, 2.5 mM EDTA, 89 mM boric acid with 
a constant current of 50 mAmp for 3-4 h. Bacteriophage lambda DNA 
standards ranging from 0.125 µg to 1.0 µg were placed on the same gels 
for quantitation. 
For analysis of restriction enzyme digests the samples were elec-
trophoresed at a constant current of 17-19 mAmp for 18-20 h. HindIII 
digests of lambda DNA were run as molecular weight standards on the same 
gels. Following electrophoresis all gels were stained with ethidium 
bromide (0.5 µg/ml), placed on a u-v transilluminator and photographed 
with Polaroid type 55 film. 
Large-Scale Isolation of Recombinant Plasmid DNA. Ten milliters 
of a 50 ml overnight preculture was used to inoculate 1 L of A.B. min-
imal medium containing no antibiotics. The organism was grown with 
shaking at 35°c. When a Klett reading of 90-100 was reached, chloram-
phenicol (250 µg/ml) was added to the culture medium for plasmid ampli-
fication. Incubation was continued for 14-16 h at which time the cells 
were harvested. The plasmid DNA was isolated as outlined above for 
pBR322 (17). 
Restriction Endonuclease Digestion. Single digests of CMV_or plas-
mid DNA were performed with the restriction enzymes BamHI, EcoRI, HindIII, 
BglII or PstI. The buffer used for all digests contained SO rnM Tris-HCl 
pH 7.5, 10 rnM MgC1 2 and 50 mM NaCl and 1 mM DTT. The reaction mixtures 
were incubated at 37°c for 60 min except for those containing Pstl, which 
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were incubated at 30°C. The reactions were stopped by heating at 65°c 
for 5 min. 
For double digests the DNA was first digested with BamHI for 60 
nu·n at 37°C. Th 1 i d. d h h e sa t concentrat on was a Juste w ere necessary; t e 
second enzyme was added, and incubation was continued for another 20 min 
0 0 
at 37 C except for the PstI digests, which were incubated at 30 C. Re-
0 
actions were again stopped by heating the samples at 65 C for 5 min. In 
later experiments both enzymes were added together at the beginning of 
the double digestion and allowed to react for a total of 60 min in the 
buffer described above. 
Southern Blotting. Identification of selected cloned fragments 
was carried out by standard hybridization techniques (80,114). CMV DNA 
was digested with BamHI, EcoRI or HindTII and subjected to agarose gel 
electrophoresis as outlined above, and the gel was stained with ethidium 
bromide for 1 h. The DNA was nicked by exposing the gel for 4 min to 
u-v light using a transilluminator. The gel was destained with distilled 
H20 for 30 min, washed with gentle agitation two times for 15 min each 
with 0.5 M NaOH/1.5 M NaCl and neutralized by washing two times for 20 
min each with 0.5 M Tris-RC! pH 7.5/1.5 M NaCl. The DNA was then trans-
ferred from the gel to a nitrocellulose filter overnight using a BRL 
blotting apparatus with !OX SSPE buffer (1.8 M NaCl, 100 mM NaH2Po4 .H20, 
10 mM EDTA). At the end of the transfer the gel was restained with ethi-
dium bromide and photographed to determine how much DNA remained. The 
filter was baked in a vacuum oven at 80°c for 2 h and then placed in a 
heat-seal bag. 
Nick Translation. Nick translation (106) of the probe DNA was per-
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formed using a nick translation kit (Amersham). The probe reaction mix-
ture contained 1-2 µg probe DNA, 20 µl buffer solution, 1-2 µl (a- 32P)-
dCTP (10-20 µCi) and 10 µl of enzyme solution in a volume of 100 µl. 
0 The reaction was allowed to proceed at 15 C for 90 min at which time it 
was stopped by the addition of 100 µl of 0.02 M EDTA containing 0.2% SDS. 
The probe mixture was loaded on a 10 ml Sephadex G-50 column equilibrated 
in 50 mM Tris-HCl, 10 mM EDTA. Progress down the column was monitored 
with a Geiger counter. Approximately 1.5 ml.of buffer containing the 
probe was collected after the predetermined void volume. The probe was 
denatured by heating to 95°c for 10 min then quick-cooled on ice. 
Hybridization. Prehybridization of nitrocellulose filters was 
carried out in heat-seal bags containing a solution of 5X SSPE, 0.3% SDS 
and 100 µg/ml denatured calf thymus DNA. Approximately 30 ml of the pre-
hybridization fluid was added for a 20 x 20 cm filter, and the sealed 
bag was incubated at 65°C for at least 1 h. 
The GeneScreen Plus membranes (New England Nuclear) were prehy-
bridized according to the manufacturer's protocol in a solution contain-
ing 0.2% PVP, 0.2% ficoll 400, 0.2% BSA, 0.05 M Tris-HCl pH 7.5, 1 M NaCl, 
0.1% sodium pyrophosphate, 1% SDS, 10% dextran sulfate and 100 µg/ml calf 
thymus DNA. The prehybridization was carried out in a heat-seal bag at 
65°c for 6 h ~ith t t "t t• " cons an ag1 a ion. 
Half of the probe sample was added to the nitrocellulose filters 
in fresh hybridization fluid in the heat-seal bag. Hybridization was 
carried out at 65°c overnight. The filter was removed and washed with 
gentle agitation four times for 30 min each at 45°c in 100-150 ml 2X SSPE 
containing 0.2% SDS. The filter was dried for 2 h at room temperature 
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and then placed between two pieces of Kodak X-Omat AR X-ray film in a 
cassette with Cronex Lightning Plus intensifier screens {Dupont). The 
0 
cassette was held in a -70 C freezer for 19-20 h. 
For the GeneScreen Plus membrane hybridizations the denatured 
probe was added to the prehybridization fluid along with 100 µg/ml de-
natured calf thymus DNA. The membranes were incubated with agitation 
for 36-48 h. 
The washing procedure for the GeneScreen Plus membranes was as 
follows: twice with 100 ml 2X SSC at room temperature for 5 min each; 
twice with 200 ml 2X SSC/1% SDS at 65°C for 30 min each; twice with 
100 ml O.lX SSC at room temperature for 30 min each. Membranes were air-
dried and placed in an X-ray cassette as previously described. 
Preparation of Filters for Direct Cell or Virus Hybridization. 
MRC-5 cells grown in 16 x 125 nun tubes or 25 cm2 flasks were infected 
with CMV AD169 or clinical CMV isolates. The inoculum consisted of dif-
ferent dilutions of the virus, and infection was allowed to proceed for 
various periods of time. The cells were harvested by trypsinization, 
washed in IX EBSS, pelleted at 1500 rpm for 15 min in a Beckman Model 
TJ-6 centrifuge and resuspended in 100-200 µl of EBSS. Appropriate di-
lutions of the cell suspensions were also made. Nitrocellulose or Gene-
Screen Plus membranes were spotted with 5 µl of the cell suspensions or 
dilutions and allowed to air dry. The membranes were processed by 
placing them on top of strips of Whatman 3MM chromatography paper· soaked 
in the following solutions as described by Brandsma and Miller (7): 0.5 M 
NaOH for 7 min; 0.6 M NaCl/0.5 M Tris-HCl pH 6.8 twice for 1 min each; 
1.5 M NaCl/0.5 M Tris-HCl pH 7.5 for 5 min. The membranes were air-dried 
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for 20 min, floated on 95% ethanol and again air-dried for 5 min. They 
were then washed twice in chloroform, air-dried for 15 min and washed 
with 0.3 M NaCl. The nitrocellulose filters were baked in a vacuum oven 
0 
at 80 C for 3 h; the GeneScreen Plus membranes r~quired no baking. 
Extracellular samples of the different virus strains or purified 
viral DNA were also spotted directly on GeneScreen Plus membranes. To 
f . 2 place more than 20 µl o the sample in a 2 cm area it was necessary to 
spot 10 µl aliquots and allow the filter to dry. Additional 10 µl ali-
q uots could then be spotted over the same area as long as complete 
drying occurred between applications. These membranes were prepared for 
hybridization in the same manner as those spotted with cells. 
In later experiments a Minifold (Schleicher & Schuell, Keene, NH) 
dot blot filtration apparatus was used to prepare GeneScreen Plus mem-
branes for direct hybridization of the probe to infected cells or cell-
free virus DNA. The membrane was prepared by suctioning lX SSC through 
the wells. Sample volumes up to 0.5 ml could then be placed in the 
appropriate wells and filtered under slight vacuum. 
Processing of Clinical Specimens. Ten milliliter samples of urine 
specimens submitted for CMV culture were collected and stored at -70°c 
in a 15 ml centrifuge tube for simultaneous analysis. The samples were 
thawed at 55°c. The urines were centrifuged at 3,000 rpm for 5 min in 
a Beckman TJ-6 centrifuge, and the supernatants were transferred to 
15 ml Corex tubes (Corning). The samples were centrifuged at 14,000 rpm 
for 90 min at 4°C in a Sorvall SS34 rotor. The supernatant was dis-
carded; the pellet was treated with 0.25 ml of 0.3 M NaCl/0.5 M NaOH; 
the samples were vortexed briefly and allowed to stand for 15 min at 
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room temperature. An equal amount of 1 M sodium acetate was added. The 
entire sample was placed in a well of the Minifold filtration apparatus 
and drawn through the GeneScreen Plus membrane with a slow vacuum. The 
membranes were then treated according to the above procedure for spot-
ting of infected cells or cell-free virus. The hybridization procedure 
was also the same as previously described. In addition to autoradio-
grams of the membrane, scintillation counting was performed on specimen 
squares cut from the membrane. 
Nick Translation of Biotinylated Probe DNA. Nick translation of 
pNSL225 was carried out according to the Enzo-Biochem protocol for the 
nick translation kit. Tritiated dATP (12 µl) was lyophilized in a 1.5 ml 
centrifuge tube to remove the ethanol. Following lyophilization the kit 
reagents were added in order: 5 µl nick translation buffer, 5 µl nucleo-
side triphosphate solution, 5 µl biotinylated dUTP, 1 µg DNA, 4 µl 
DNase I (appropriately diluted), 4 µl DNA polymerase I, water for a 
final volume of 50 µl. The reaction mixture was placed in a 14°C water 
bath for 2 h. To stop the reaction 5 µl of the stop buffer (0.2 M EDTA) 
was added. 
The biotinylated probe was separated from unincorporated nucleo-
tides on a 3.5 ml Sephadex G-50 column equilibrated with 10 mM Tris-HCl 
pH 7.5, 1 mM EDTA. Five-drop fractions were collected; 2 µl aliquots 
of each fraction were counted by liquid scintillation. Fractions for-
ming the first peak of radioactivity were collected and pooled. 
Alternatively the reaction mixture was placed on a spin column. 
The spin column was constructed as described in the Enzo-Biochem pro-
tocol using a 1 ml tuberculin syringe filled with Sephadex G-50 equili-
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brated with 10 mM Tris HCl, 1 mM EDTA and placed inside a 15 ml conical 
centrifuge tube. The column was packed by low-speed centrifugation 
(1500 rpm for 4 min in a Beckman TJ-6 centrifuge). A 1.5 ml Eppendorf 
tube was used to collect the probe material which passed through the 
column following low-speed centrifugation under the exact conditions 
used to pack the column. 
Hybridization and Detection of Biotinylated Probe. Prehybridiza-
tion of spotted membranes was carried out according to the GeneScreen 
Plus manufacturer's protocol as described above. The hybridization 
solution contained: 0.02% PVP, 0.02% ficoll 400, 0.02% BSA, 5X SSC, 50% 
formamide, 20 mM Na phosphate buffer pH 7.0, 10% dextran sulfate, 0.1% 
SDS, 1 mg/ml freshly boiled calf thymus DNA, 200-500 ng/ml freshly 
boiled probe DNA. The membranes with the hybridization fluid were placed 
0 . 
in a heat-seal bag and incubated with shaking at 42 C for 24-48 h. At 
the end of this period the membranes were washed as follows: twice for 
15 min each in 2X SSC/0.1% SDS at room temperature; twice for 15 min 
0 
each in the same solution at 65 C; once in 2X SSC alone for 15 min at 
room temperature. 
The washed membranes were blocked in a dish containing a solution 
of 2% BSA and 0.1% Triton X-100 in lOX PBS for 1 h at 37°c. The horse-
radish peroxidase complex (Detek I-hrp) was diluted in buffer as pro-
vided by the detection kit, added to the membranes in a heat-seal bag 
and incubated for 30 min at 37°c. The membranes were then removed from 
the bag and washed as follows: 3 times for 5 min each in 0.5 M NaCl, 
10 mM phosphate buffer pH 6.5. 0.1% BSA, Tween 20 (0.5 ml/l) at room 
temperature; 2 times with 2X SSC, 0.1% BSA, Tween 20 (0.5 ml/l). 
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The enzyme substrate was prepared by adding 10 ml of 10 mM Tris-
HCl pH 7.5 to 2.5 mg of diaminobenzidine tetrahydrochloride (DAB). 
Cobalt chloride (100 µl of a 1% solution) was added to the DAB, which 
was then placed on ice for 10 min in the dark. Finally 7.5 µl of 30% 
H2o2 was added, and the solution was applied to the membrane in a heat-
seal bag. The bag was placed in the dark for 10 min for full color 
development. After this time the membrane was washed with 2X SSC and 
examined for probe hybridization. 
RESULTS 
Growth Characteristics, Titer and Plaque Purification of CMV. 
Samples of CMV AD169 could be passaged in culture from the extracellu-
lar tissue culture fluid once the CPE had reached approximately 50%. 
Higher extracellular titer, however, occurred 2-4 days after 100% CPE 
was reached (57,124). Attempts to passage cell-free fluid with less 
than 50% CPE were routinely unsuccessful, although passage of infected 
cells to new monolayers was possible whenever there was detectable CPE. 
Three clinical isolates (LU-1, LU-2, LU-3) were originally highly 
cell-associated. In infected monolayers the CPE remained less than 25% 
even after weeks of culture. Monolayers were repeatedly passaged when 
CPE had been visible for 1-2 weeks. After approximately 4-5 passages of 
infected monolayers over a period of several months, the virus became 
less cell-associated. CPE progressed to 100% of the monolayers, and 
passage of the tissue culture fluid alone was sufficient to infect new 
monolayers. Continued passage of the supernatant fluid of these strains 
resulted in a further increase in the titer of the extracellular fluid 
(Table 1). 
For all strains of CMV it was necessary to passage the virus at a 
low MOI (less than 1) to achieve a high extracellular virus titer. The 
ntnnber of defective particles increases when the MOI is greater than 
one, which means the pfu to particle ratio decreases (16,112, Table 1). 
The titers were determined by the plaque assay method of Wentworth 
and French (140) except that 24-well plates were used instead of 60 mm 
37 
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TABLE 1 
Titers of CMV strains after passage. 
Isolate Original Titer after 
Number Titer (p'fu/ml) Passage (pfu/ml) MOI 
AD-169 lxl06 2xl02 >l 
AD-169 6 7 lxlO -lxlO 6 7 lxlO -lxlO 0.01-0.001 
LU-1 2xl05 4.5xl0 7 0.01-0.001 
LU-2 lx104 lxl06 0.01-0.001 
LU-3 lxlo5 l.5xl0 6 0.01-0.001 
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dishes. This change made it possible to inoculate a larger number of 
replicate cultures with fewer cells for each assay. One other modifica-
tion involved plating the cells well below confluency and allowing them 
to grow for 24-48 h to slight subconfluency. The cells were then much 
more adherent and less easily disrupted by the virus inoculation and 
subsequent agarose overlay. For the isolates of AD169 and the clinical 
strains LU-1, LU-2, LU-3, the highest extracellular titer observed was 
7 4.5 x 10 (Table 1). Depending on the passage and growth conditions the 
titers usually ranged between 1 x 106 and 1 x 107, which is lower than 
8 the optimal titer of 5 x 10 reported for the CMV Towne strain (75). 
The use of roller bottles, however, increased the titer approximately 
ten-fold (Table 2). 
The plaque assays were also used for plaque purification. By 
selecting wells in which there were fewer than 5 plaques it was possible 
2 to pick isolated plaques for passage to 25 cm flasks. It was necessary, 
however, to wait until there was some clearing of the cells in·an in-
fected focus to assure the presence of extracellular virus in the over-
lay medium. This usually required 5-7 days from the initial appearance 
of the focus. Since the plaques were selected from the highest dilu-
tions, the time from inoculation to the appearance of plaques in these 
wells was generally 12-14 days. With additional time to clearing of the 
plaque the total time required for plaque selection was about 3 weeks. 
. 2 
The plaque-purified inoculum was then passaged to HFS cells in 25 cm 
flasks at an MOI between 0.01 and 0.001 to propagate the virus for fur-
ther plaque purification or for freezing for stock samples. Aliquots of 
the final plaque-purified samples were examined by electron microscopy 
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TABLE 2 
Effect of culture vessel on titer of CMV AD169. 
Titer of 
Experiment Culture Vessel Supernatant Total Virus 
Number (pfu/ml) Yield (pfu) 
1 24 flasks (150 2 cm ) 2x10 7 l.7xlo10 
2 24 flasks (150 2 cm ) lxl0 7 8.4xl0 9 
3 10 roller bottles 4x108 5.0xlo11 
(850 cm2) 
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for morphological confirmation, that the virus was CMV. 
To obtain a stock of AD169 for large-scale isolation of DNA the 
original sample was plaque-purified three times. The final stock virus 
had a titer of 2.5 x 107• To maintain the stock a 1 x 10-6 dilution of 
2 the plaque-purified virus was passaged in 25 cm flasks. When the MOI 
was appropriately low, CPE did not appear for at least 7 days after in-
oculation. A very few discrete foci 'of infection appeared at that time, 
and these progressed to 100% CPE by 12-14 days. The extracel~ular fluid 
was ready for harvest 3-4 days later. 
Large-Scale Growth and Purification of Virions. Several modifi-
cations were made in this procedure because there was difficulty in 
obtaining sufficient quantity of virus for DNA extraction. In the ear-
liest experiments the virus was propagated in 24 tissue culture flasks 
(150 cm2), which yielded about 850 ml of culture fluid and titers of 
approximately 1 x 10 7 pfu/ml. To increase the total virus yield 850 cm2 
roller bottles were used. The total surf ace area of the inoculated 
2 
monolayers was more than twice the total area of the 150 cm flasks, and 
at the same time the total tissue culture fluid volume required to main-
tain the roller bottle cultures was only 1.5 times greater than the 
volume for the flasks (1200 ml versus 850 ml). 
In all purification procedures attempted the supernatant fluid 
was first cleared of cell debris by low-speed centrifugation. In the 
earliest experiments the virus was pelleted by ultracentrifugation 
through a sorbitol cushion (124,126), which allows the best preservation 
of infectivity. A modification which was introduced later was the use 
of 5% PEG 6000 to precipitate the virus from the supernatant fluid fol-
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lowed by low-speed centrifugation to pellet the virus (34,52). There 
were visible viral pellets obtained with both of these methods, but the 
total yield was still insufficient for adequate DNA extraction (Table 3). 
Further purification steps in both of the above procedures in-
volved the use of a discontinuous CsCl gradient (124) or a discontinuous 
sorbitol gradient (130). Both of these manipulations appeared also to 
decrease the final virion yield, although visible bands appeared at the 
appropriate interfaces (Table 3). 
To follow the virus through these purification steps the original 
cultures were labelled with 3H-thymidine. In addition the infectivity 
of the material obtained after each step was tested. In most of the ex-
periments there was significant radioactivity and infectivity associated 
with the collected samples. 
The problems encountered in the earlier attempts to purify the 
virus seemed to involve either insufficient initial viral titer or loss 
of virions during purification. To simplify the procedure the clarified 
supernatant fluid from 10 roller bottles was directly pelleted at 23,430 
x g without a sorbitol cushion or PEG precipitation (75). This modifi-
cation led to the successful collection of a sufficient quantity of 
virus for DNA extraction. 
Extraction of DNA. The procedure published by Stinski et al. 
(124,126) was followed for the first attempts to extract viral DNA. The 
virions were lysed and digested with Sarkosyl, SDS and proteinase K. The 
lysate was added to CsCl with ethidium bromide (50 µg/ml) at a density 
3 
of 1.56 g/cm • At equilibrium the ethidium bromide was present as a 
red band at the interface of the CsCl solution and the mineral oil. 
Table 3. Stunmary of DNA isolation procedures. 
Experi- Gradient 
ment Culture Sorbitol PEG Purification Ly sis 
Number Vessel Cushion ppt of Virions Procedure 
1 24 flasks + - 20-70% Sorbitol Sarkosyl/SDS 
(150 cm2) CsCl(l. 26g/ml) Proteinase K 
2 24 flasks + - 20- 70% Sorbi tol Sarkosyl/SDS 
(150 cm2) Discontinuous Proteinase K 
CsCl(l.2/l.4g/ml) 
3 24 flasks + - Discontinuous SDS 
(150 cm2) Sorbitol Pronase 
(75/48/20%) 
4 24 flasks - + Discontinuous SDS 
(150 cm2) Sorbitol Pronase 
(75/48/20%) 
5 24 flasks - + Discontinuous SDS 
(150 cm2) Sorbitol Pronase 
(75/48/20%) 
6 & 7 10 roller - - - Sarkosyl 
bottles SDS 
(850 cm2) Pronase 
Gradient 
Purification 
of DNA 
CsCl/EtBr 
(1. 56g/ cm3) 
CsCl/EtBr 
( 1. 56 g/ cm3) 
Cs Cl 
( 1. 72g/ cm3) 
Cs Cl 
( 1. 72g/ cm3) 
Cs Cl 
(1. 72g/ cm3) 
-
Results 
No DNA detected 
No DNA detected 
Radioactive peak 
Faint band of DNA 
on agarose gel 
Radioactive peak 
No band of DNA on 
agarose gel 
Radioactive peak 
Faint band of DNA 
on agarose gel 
Total yield 2.5 µg 
DNA at a concentra-
of "' 12.5 µg/ml 
~ 
w 
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The band was apparent under normal light and was brightly fluorescent 
under u-v light. There was no fluorescent band of DNA at the appropriate 
density and no peak of radioactivity. Similar results occurred repeat-
edly with this procedure. 
A second lysis procedure was followed in which the virions were 
treated with SDS, RNase A and pronase (130). The lysate was added to 
CsCl without ethidium bromide at a density of 1.716 g/cm3• This is the 
density of CMV DNA, which is significantly different from that of cell-
3 
ular DNA (1.69 g/cm ), thus, there should have been no difficulty in 
separating viral DNA from any cellular DNA contamination. In fact only 
a single peak of radioactivity was present in any of the CsCl gradients 
performed on viral lysates, and this peak was always very close to a den-
sity of 1.716 g/ml (Figure 3). In two experiments the material recovered 
from the CsCl produced a faint band following agarose gel electrophoresis. 
A rough estimation of the concentration of the DNA based on lambda DNA 
standards was less than 1 µg/ml. Attempts to concentrate the DNA by 
ethanol precipitation were, however, unsuccessful. In spite of the fact 
that there appeared to be a small quantity of DNA extracted in each ex-
periment, there was not enough to perform restriction endonuclease di-
gestion analysis or to clone the fragments. 
The method of DNA extraction which was finally successful was a 
modification of the procedure of LaFernina and Hayward (75). The pel-
leted virus, which was resuspended in buffer, was first subjected to 
RNase digestion before lysis of the virions. This differed from the pub-
lished procedure, which called for the addition of RNase at a later stage 
in the extraction process. It seemed reasonable to remove contaminating 
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Figure 3. Fractions from CsCl gradient containing CMV AD169 DNA. 
The DNA sample was added to CsCl at a density of 1.716 
g/cm3 and centrifuged in a Beckman type 50 rotor at 
35,000 rpm for 48 h. Fractions (35 drops each) were 
collected from the bottom, and the radioactivity of 
20 µl aliquots of each fraction was determined. 
O= cpm per fraction for 3H-labelled DNA 
D= density g/ml per fraction 
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RNA before release of the DNA, since viral lysis should not produce any 
additional RNA. 
After the RNase treatment the virion suspension was lysed directly 
with Sarkosyl and SDS, which resulted in almost complete clearing of. the 
fluid. The subsequent addition of pronase removed any residual tur-
bidity. Another modification in the procedure was the incubation time 
in the presence of pronase. Two hours rather than overnight seemed to be 
sufficient for the digestion. Following phenol and chloroform extrac-
tions the lysate was dialyzed directly without purification in a CsCl 
gradient. Since no gradient was involved, radioactive labelling of the 
DNA was not necessary, and there was less chance of losing DNA with 
additional manipulations. The dialysate was concentrated by ethanol pre-
cipitation, and the resulting DNA sample contained approximately 2.5 µg 
' 
at a concentration of 12.5 µg/ml (Figure 4). 
Isolation of Plasmid pBR322. The plasmid pBR322 was chosen as the 
cloning vector for CMV DNA fragments. The source of the plasmid was ].. 
coli strain RRl. Following extraction from the bacteria the plasmid DNA 
was centrifuged in CsCl (1.65 g/ml) with ethidium bromide at 38,000 rpm 
in a VTi 50 rotor for 38 h. At equilibrium there were two bands about 
two-thirds of the way down the gradient. The upper portion of the gra-
dient including the upper band containing chromosomal DNA was removed 
from above. The lower band of plasmid DNA was collected in a total vol-
ume of 2.4 ml. The ethidium bromide was extracted with isopropanol sat-
urated with 20X SSC. After overnight dialysis, 5 and 10 µl samples were 
loaded on an agarose gel along with a known isolate of pBR322 (a gift 
of Dr. S.K. Farrand). Bands which were assumed to represent linear, open 
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Figure 4. CMV AD169 DNA after ethanol precipitation. Electro-
phoresis was performed on a 0.7% agarose gel at a con-
stant current of 40 mAmp for 3 h. After electrophor-
esis the gel was stained with ethidium bromide. 
Lanes: (1) CMV AD169 DNA 
(2) A DNA 0.125 µg 
(3) A DNA 0.25 µg 
(4) A DNA 0.50 µg 
(5) A DNA 1.0 µg 
1 2 3 4 5 
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circle and supercoiled plasmid DNA were present in both pBR322 prepara-
tions. The corresponding forms of these two plasmid isolates migrated 
to the same points in the gel indicating that the newly isolated plasmid 
was probably pBR322. 
For further proof of the identity of the plasmid, restriction 
endonuclease analysis was performed. If all the bands on the gel rep-
resented forms of pBR322, then digestion with a restriction enzyme which 
had only one cleavage site in this plasmid should produce homogeneous 
linear fragments to form a single band after gel electrophoresis. 
Double enzyme digests would provide even more information. The plasmid 
and the known isolate of pBR322 were, therefore, treated with the re-
striction enzymes HindIII, HinfI or both. HindIII digestion produced 
a single band of linear DNA, since there is only a single HindIII site 
in pBR322 (80). This band migrated with the 4.34 kb fragment of a 
HindIII digest of A DNA, which would be expected since the size of 
pBR322 is 4.3 kb. HinfI digestion produced ·several fragments the larg-
est of which (A fragment) is 1.1 kb in size. This HinfI A fragment has 
a single HindIII site. As expected double digestion of the plasmid with 
HinfI and HindIII, produced two smaller bands of the appropriate size 
from the original A fragment. 
The restriction enzyme patterns observed confirmed that the sam-
ple plasmid was pBR322. The bands matched those of the standard pBR322 
preparation when digested with the same restriction enzymes. In addi-
tion the double digest produced the expected change in the HinfI A frag-
ment. 
Cloning of CMV AD169 DNA Fragments in pBR322. BamHI was selected 
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for the cloning procedure, because insertion at the BamHI site in the 
vector pBR322 consistently inactivates the tetracycline resistance 
carried by the plasmid (80). The disadvantage of BamHI is that it 
cleaves the CMV genome into more fragments than other restriction en-
zymes such as HindIII or XbaI (49,141). E. coli strain SF8 was selected 
for the subsequent transformation. 
The first attempt at cloning produced only twelve transformants 
of which two were recombinants demonstrating tetracycline sensitivity. 
One contained a double insert of two small fragments of around 2 kb each, 
and the second contained a single insert co-migrating with the smaller 
insert of the other recombinant. The ligation control plates showed no 
transformants, but the supercoiled pBR322 control DNA produced a large 
number of transformants. These results suggested that components of the 
ligation reaction mixtures were inhibiting transformation. During the 
cloning procedure neither the CMV and vector DNA digests nor the liga-
tion mixture were ethanol precipitated. For the second cloning attempt 
ethanol precipitation was performed after both of these steps. Of 482 
ampicillin resistant colonies 67 were shown to be tetracycline sensitive 
indicative of recombinant inserts. They have been repeatedly passed on 
nutrient agar containing 100 µg/ml ampicillin. The sensitivity to tetra-
cycline has been retained indicating that the recombinants are stable. 
Analysis of Plasmid Inserts. All of the 67 recombinants were 
analyzed for plasmid content by the method of Holmes and Quigley (55). 
On the basis of the migration of the plasmids relative to intact pBR322 
the size of the inserts was classified as small, medium or large. Those 
plasmids which migrated the slowest were selected for restriction diges-
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ion with BamHI to determine whether they contained single or multiple in-
serts. The plasmids pNSL215 and pNSL225 appeared to have the largest 
single inserts and were chosen for large~scale isolation as potential 
probes. The reason large fragments were considered desirable was the 
greater likelihood that they would contain base sequences homologous to 
all strains of CMV. 
A second set of recombinants was analyzed for medium-sized in-
serts which might contain the U fragment present in the long repeat 
segments of the CMV genome (45). This fragment lies completely within 
the long inverted repeats and is, therefore, present in 2 molar quantity 
in the complete genome digests (Figure 2). Choosing such a fragment as 
a probe would allow two possible points of homology provided there is 
not a great deal of variability among CMV strains in this part of the 
inverted repeat regions. Two recombinants, pNSL45 and pNSL186, were 
found to have inserts which migrated with the doublet band containing 
the T and U fragments. These also were subjected to large-scale isola-
tion for further identification. 
Identification of Inserted Fragments in Selected Recombinant 
Plasmids. The first step in the identification of the fragments carried 
by the four selected recombinants (pNSL45, pNSL186, pNSL215, pNSL225) 
involved double restriction enzyme digests. The restriction enzyme map 
of CMV AD169 from Greenaway et al. (49) (Figure 2) was used to choose 
the appropriate enzymes. 
The plasmids pNSL215 and pNSL225 appeared to migrate with the 
first band of the BamHI digest of CMV DNA. This band contains the co-
migrating fragments A and B (15 kb). There was also the possibility 
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that the closely-migrating fragment C (14 kb) could be the insert. The 
enzymes EcoRI and HindIII were selected for double digests with BamHI. 
The A fragment has 3 EcoRI sites and 2 HindIII sites; the B fragment has 
1 HindIII site and 1 EcoRI site; the C fragment has 2 HindIII sites and 
no EcoRI sites. EcoRI and HindIII cut pBR322 alone very close to the 
same site, thus a double digest of either enzyme with BamHI should yield 
a larger 4 kb fragment and a smaller 0.3 kb fragment for the pBR322 por-
tion of the recombinant plasmid. 
Figure SA shows the results of these digests. Lane 11 is pBR322 
digested with BamHI, which results in a single band of linear DNA. 
Lanes 3 and 4 are double digests of pBR322 with BamHI/HindIII and BamHI/ 
EcoRI respectively. The major pBR322 fragment (4 kb) is slightly smaller 
than the single BamHI digested pBR322 as predicted. Lanes 7 and 10 are 
BamHI digests of each recombinant with the large insert intact. Lanes 
6 and 9 are BamHI/EcoRI double digests of each recombinant. In both 
cases the insert has been cut. Lanes S and 8 are the BamHI/HindIII 
double digests. The inserts do not appear to have been altered by 
HindIII, because the HindIII recognition site is only about 0.3 kb from 
the end of the fragment. 
To rule out the possibility that the inserts in the recombinant 
plasmids could be the D fragment, further double digests with BamHI plus 
PstI, BglII and XbaI were performed. The digest pattern is shown in 
Figure SB. The insert is cut by PstI into three larger fragments plus 
2 very small fragments (Lane S). XbaI cuts the insert only once (Lanes 
7 and 9), and BglII produces 1 larger fragment plus 3 small fragments 
(Lanes 6 and 8). 
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Figure 5. Double restriction enzyme digests of plasmids carrying 
the BamHI B fragment insert. 
A. Lanes: (1) pBR322 uncut; (2) CMV AD169 BamHI; 
(3) pBR322 BamHI/EcoRI double digest; (4) pBR322 
BamHI/HindIII double digest; (5) pNSL225 BamHI/ 
_!iindIII; (6) pNSL225 BamHI/EcoRI; (7) pNSL225 BamHI; 
(8) pNSL215 BamHI/HindIII; (9) pNSL215 BamHI/EcoRI; 
(10) pNSL215 BamHI; (11) pBR322 BamHI. 
B. Lanes: (1) pBR322 BamHI; (2) pNSL215 BamHI; 
(3) pNSL215 BamHI/EcoRI; (4) pNSL215 BamHI/HindIII; 
(5) pNSL215 BamHI/PstI; (6) pNSL215 BamHI/BglII; 
(7) pNSL215 BamHI/XbaI; (8) pNSL225 BamHI/BglII; 
(9) pNSL225 BamHI/XbaI; (lO)A HindIII. 
<( 
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It can be concluded, therefore, that the double digests of both 
plasmids are ~onsistent with the pattern which would be predicted for 
the B fragment. Single HindIII or EcoRI digests were performed on 
pNSL215 and pNSL225 to determine the orientation.of the inserts (Fig-
ure 6). Both HindIII digests (Lanes 4 and 5) have two fragments approx-
imately 4.3 kb and 15 kb in size. The EcoRI digests (Lanes 3 and 4) 
each show fragments of about 9 kb and 10.3 kb. The opposite orientation 
of the insert in the plasmids would yield HindIII fragments of 0.6 kb 
and 18.7 kb, and EcoRI fragments of 5.3 kb and 14 kb. The orientation 
of the inserts is, therefore, the same in these two plasmids. The re-
striction patterns for both enzymes (HindIII and EcoRI) are consistent 
with orientation I depicted in Figure 7. 
The double digests for the 2 recombinants suspected of carrying 
the U fragment are shown in Figure 8. The restriction enzymes BamHI 
plus PstI, EcoRI and HindIII were used to distinguish the U fragment from 
the QRS (6.5 kb), T (5.6 kb) and V (5.4 kb) bands. The U fragment should 
have no HindIII or PstI sites and a single EcoRI site (Figure 2). The T 
fragment has at least 3 PstI sites. Fragments QRS and V all have sites 
for at least 2 of the 3 enzymes. From Figure 8 it can be seen that both 
plasmids carry inserts which are not cut by HindIII (Lanes 9 and 13) or 
PstI (Lanes 7 and 11), but which are cut by EcoRI (Lanes 8 and 12). 
~- -~ 
Again the patterns of the two plasmids appear identical, therefore; both 
apparently contain the U fragment. 
The second approach to the identification of the inserted frag-
ments in the selected recombinants was to produce radiolabelled probes 
by nick translation of the recombinant plasmids and to hybridize them to 
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Figure 6. Single restriction enzyme digests of pNSL215 and pNSL225 
to determine the orientation of the CMV AD169 BamHI 
B fragment insert at the BamHI site in pBR322. 
Lanes: (1) A. DNA (0.25 µg) digested with HindIII 
.(2) pNSL215 EcoRI 
(3) pNSL225 EcoRI 
(4) pNSL215 HindIII 
(5) pNSL225 HindIII 
(6) A. DNA (0.75 µg) HindIII 
1 2 3 4 5 6 
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Figure 7. Restriction enzyme maps of pNSL215 or pNSL225 showing 
fragments expected for each possible orientation. The 
CMV AD169 BamHI fragment B insert is at the BamHI site 
in pBR322. The enzyme recognition sites (arrows) are: 
BamHI (B), HindIII (H) and EcoRI (E). Fragment sizes 
produced by digestion with either HindIII or EcoRI for 
each orientation are given. 
ORIENTATION I 
Hind III EcoRI 
ORIENTATION 
PNSL215/225 PNSL215/225 
Hind III 
"2RI 
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Figure 8. Double restriction enzyme digests of plasmids carrying 
the BamHI U fragment insert. 
Lanes: (1) pNSL186 uncut; (2) pNSL45 uncut; (3) pBR322 
BamHI/PstI double digest; (4) pBR322 BamHI/EcoRI; 
(5) pBR322 BamHI/HindIII; (6) pBR322 BamHI; (7) pNSL186 
BamHI/PstI; (8) pNSL186 BamHI/EcoRI; (9) pNSL186 BamHI/ 
HindIII; (10) pNSL186 BamHI; (11) pNSL45 BamHI/PstI; 
(12) pNSL45 BamHI/EcoRI; (13) pNSL45 BamHI/HindIII; 
(14) pNSL45 BamHI; (15) A digested with HindIII 
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different enzyme digests of total CMV DNA. For the two plasmids pNSL215 
and pNSL225 the CMV DNA was digested with EcoRI, HindIII and BamHI. A 
probe was made with pNSL225. The CMV DNA digests show that the probe 
binds to a single large BamHI fragment, a large HindIII fragment and 2 
large EcoRI fragments (Figure 9). This is consistent with the pattern 
expected for the B fragment of the BamHI digest. There is a short se-
quence (~ 0.3 kb) at the end of the B fragment which would be expected to 
be homologous to the HindIII L fragment (Figure 2). Hybridization of the 
probe to this HindIII fragment is not distinguishable in Figure 9, al-
though the existence of a HindIII recognition site in the insert was dem-
onstrated by the HindIII digests of pNSL215 and pNSL225 (Figure 6). The 
co-migrating BamHI A fragment however, should hybridize to 4 EcoRI frag-
ments and 3 HindIII fragments. The BamHI C fragment should hybridize to 
only 1 EcoRI fragment and 3 HindIII fragments. The hybridization re-
sults (Figure 9) do not support the possible presence of either of these 
inserts. 
The hybridization experiment to identify the U fragment is more 
difficult to interpret. Since the U fragment is part of the long repeats, 
it can hybridize to joint fragments comprising the junction of the long 
and short repeat sequences in other restriction enzyme digests (Figure 1). 
These joint fragments (L-S) are present in less than 1 molar concentra-
tions, because there are four possible configurations of the CMV genome. 
The T fragment as well as QRS and V are present only in the unique se-
quences, and therefore, have better defined hybridization patterns. In 
Figure 10 it can be seen that the probe which was made from pNSL45 hy-
bridized to several large HindIII fragments some of which appear to be 
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Figure 9. Southern hybridization of 32P-labelled B fragment probe 
(pNSL225) with restriction enzyme digests of total CMV 
AD169 DNA. Autoradiogram shown above with corresponding 
agarose gel below. Exposure time 19 hours. 
Lanes: (A) pNSL225 BamHI digest; (B) CMV AD169 DNA 
BamHI; (C) CMV AD169 HindIII; (D) CMV AD169 DNA EcoRI. 
A I c D 
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placed on the same gels for blotting to nitrocellulose. In Figure 11 it 
can be seen that the B fragment probe did not hybridize to any fragments 
of the three viruses, while the appropriate hybridization with the CMV 
DNA digest clearly occurred. It should be noted that there was less EBV 
DNA than CMV DNA present on the gel. Similar amounts of CMV AD169 DNA 
produce strong hybridization with the probe, but there is 100% homology 
between the CMV DNA and the probe. It could be argued that partial 
homology with EBV DNA in such low quantity would not be detected. A 
southern blot using the U fragment probe also showed no hybridization to 
the DNA digests of these other herpesviruses. 
Hybridization of the Probe with Infected Cells. The initial ex-
periment was set up in duplicate using both a nitrocellulose filter and 
GeneScreen Plus membrane for comparison. MRC-5 cells in 16 x 125 mm 
tubes were inoculated starting 10 days before the expected harvest date. 
Two tubes each day were inoculated with a 10-5 dilution of stock plaque-
purified CMV AD169. On the day of harvest the cells were trypsinized 
and two ten-fold dilutions were made of the cells from each day of in-
oculation. The filters were spotted with 5 µl volumes representing 104 , 
103, and 102 cells from 10 days down to 2 days postinfection. In addi-
tion HSV-1, HSV-2, EBV and CMV DNA were spotted. The filters were 
treated according to the procedure of Brandsma and Miller (7). The nitre-
cellulose filter, however, was baked only 3 h instead of 18 h, and ,the 
GeneScreen Plus membrane was not baked at all. The probe was produced 
by nick translation of pNSL225. Hybridization of both filters was car-
0 
ried out in heat-seal bags at 65 C for 43 h, but the GeneScreen Plus was 
constantly agitated in a water bath, while the nitrocellulose was placed 
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Figure 11. Southern hybridization of 32P-labelled B fragment probe 
(pNSL225) with HSV-1, HSV-2, EBV and CMV AD169 total 
DNA BamlII digests. Autoradiogram shown above with cor-
responding agarose gel below. Exposure time 20 hours. 
Lanes: (A) pNSL225 BamlII digest; (B) EBV BamlII; 
(C) HSV-2 BamlII; (D) HSV-1 BamlII; (E) CMV AD169 BamlII. 
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in an oven and only occasionally flipped and rocked. 
In this first attempt to hybridize the CMV probe with infected 
cells the GeneScreen Plus membrane produced more encouraging results than 
the nitrocellulose. In both cases there was too much background hybrid-
4 ization, but there were definite spots for 10 cells from 10 to 5 days 
post-infection and for the CMV DNA. The nitrocellulose filter was much 
more difficult to interpret. The CMV DNA spot was the only definite area 
of hybridization. It was decided to use the GeneScreen Plus instead of 
nitrocellulose for future experiments, because it gave better results, 
was easier to handle and required no baking. The one disadvantage of 
GeneScreen Plus is the 6-hour minimum prehybridization reconnnended by the 
manufacturer. 
In the next experiment with infected cells the viral inocula were 
clinical isolates of CMV. The B fragment (pNSL225) was used as the probe, 
and the hybridization was performed in the same manner as that outlined 
for AD169-infected cells. Figure 12 shows that the probe hybridizes to 
all CMV isolates tested. However, as noted above there is no hybridiza-
tion to uninfected cells nor to HSV-1 and HSV-2 DNA. From this experi-
ment it can be concluded that the probe can detect more CMV strains than 
just the stock strain AD169 from which it was made, and there is no cross-
reactivity with the 2 strains of HSV which were tested. This suggests 
that this probe may have both sensitivity and specificity for CMV. The 
infected cells showed 50-80% CPE depending on the isolate, therefore, no 
quantitative conclusions can be drawn concerning the degree of sensi-
tivity nor can the possibility of cross-hybridization with other strains 
of HSV be ruled out. 
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Figure 12. Hybridization of 32P-labelled B fragment probe (pNSL225) 
with cells infected with CMV AD169 or passaged clini-
cal isolates of CMV. Exposure time 20 hours. 
Columns: (A) CMV AD169; (B) LU-1; (C) LU-2; (D) LU-3. 
Rows: (1) lx10 3 infected MRC-5 cells; (2) lxl04 in-
fected cells; (3) lxl05 infected cells. 
Control: 
Squares: 
6 lxlO uninfected MRC-5 cells 
(Gl) HSV-1 F DNA 0.1 µg 
(G3) HSV-2 333 DNA 0.1 µg 
(Hl) CMV AD169 DNA 0.01 µg 
(H4) pNSL225 DNA 0.1 µg 
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A more quantitative experiment was performed directly on virus 
particles spotted on the membrane (Figure 13). Dilutions of stock sam-
ples of three clinical isolates and AD169 were placed on the membrane 
and processed according to the method of Brandsma and Miller (7). For 
one set of dilutions for each virus sample 2.75 x 103 uninfected cells 
were spotted along with the virus. There appeared to be no significant 
difference between the virus alone and the virus plus cells for any of 
the CMV isolates. There was no hybridization with uninfected cells alone. 
HSV-1 and HSV-2-infected cells were tested along with separate samples of 
naked HSV-1 and HSV-2 DNA. There was no hybridization with the HSV-in-
fected cells and only slight hybridization with 1 µg of HSV DNA. There 
was 50 times as much RSV DNA as control CMV DNA on the membrane, there-
fore, the background hybridization with the HSV DNA is unlikely to be a 
problem in other experiments. The number of pfu which the probe detected 
6 3 6 4 
ranged from 1 x 10 to 2.5 x 10 for AD169, 1.8 x 10 to 4.5 x 10 for 
4 2 4 2 LU-1, 4 x 10 to 4 x 10 for LU-2, and 6 x 10. to 6 x 10 for LU-3. 
The hybridization of LU-3 with the probe appears as strong as that 
of AD169 and LU-1. The titer of this isolate, however, is only slightly 
higher than that of LU-2. A possible explanation of this discrepancy may 
be that there is a larger number of defective virus particles in the LU-3 
preparation. This would yield a greater amount of DNA relative to the 
number of pfu detected in the plaque assay. 
Another experiment was designed to determine how large an inoculum 
of virus might be required for detection within 72 h of inoculation of 
cells in culture. Ten-fold dilutions of an AD169 stock sample containing 
2 x 107 pfu/ml were used to inoculate MR.HF cells in 16 x 125 mm tubes. 
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Figure 13. Hybridization of 32P-labelled B fragment probe (pNSL22S) 
with cell-free virus or virus plus uninfected cells. Exposure time 
23 hours. 
6 s Columns: (A) AD169 cell-free virus: lxlO pfu (l); 2.SxlO pfu (2); 
2.Sxl04 pfu (3); 2.Sxl03 pfu (4); 2.Sxl0 3 pfu (S). 
(B) AD169 cell-free virus plus lxlo3 uninfected MRC-S cells 
(same number pfu as in column A). 
(C) LU-1 cell-free virus: l.8xl06 pfu (l); 4.SxlOS pfu (2); 
4 4.SxlO pfu (3). 
3 (D) LU-1 cell-free virus plus lxlO uninfected MRC-S cells 
(same number pfu as in column C). 
4 4 (E) LU-2 cell-free virus: 4xl0 pfu (l); lxlO pfu (2); 
3 lxlO pfu (3). 
( 3 . F) LU-2 cell-free virus plus lxlO uninfected MRC-S cells 
(same number pfu as in column E). 
4 4 (G) LU-3 cell-free virus: 6xl0 pfu (l); l.SxlO pfu (2); 
3 l.SxlO pfu (3). 
3 (H) LU-3 cell-free virus plus lxlO uninfected MRC-S cells 
(same number pfu as in column (G). 
(I) HSV-1-infected MRC-S cells (l); HSV-1 DNA, 1 µg (2); 
HSV-2-infected MRC-S cells (3); HSV-2 DNA, 1 µg (4); 
pNSL22S DNA 0.2 µg (S). 
(Z) Dilutions of CMV AD169 DNA: 10 ng (l); 1 ng (2); 
100 pg (3); 10 pg (4). Hybridization on separate mem-
brarie under same conditions as samples in columns A-I. 
Control (ES): lxl0 3 uninfected MRC-S cells. CMV AD169 DNA (GS): 20 ng 
1 
1 j 
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Figure 13. 32 Hybridization of P-labelled B fragment probe (pNSL22S) 
with cell-free virus or virus plus uninfected cells. Exposure time 
23 hours. 
6 s Colwnns: (A) AD169 cell-free virus: lxlO pfu (l); 2.SxlO pfu (2); 
2.Sxl04 pfu (3); 2.Sxlo3 pfu (4); 2.Sxl0 3 pfu (S). 
(B) AD169 cell-free virus plus lxlo 3 uninfected MRC-S cells 
(same number pfu as in column A). 
6 s (C) LU-1 cell-free virus: l.8xl0 pfu (l); 4.SxlO pfu (2); 
4 4.SxlO pfu (3). 
3 (D) LU-1 cell-free virus plus lxlO uninfected MRC-S cells 
(same number pfu as in column C). 
4 4 (E) LU-2 cell-free virus: 4xl0 pfu (l); lxlO pfu (2); 
3 lxlO pfu (3). 
3 (F) LU-2 cell-free virus plus lxlO uninfected MRC-S cells 
(same number pfu as in column E). 
4 4 (G) LU-3 cell-free virus: 6xl0 pfu (l); l.SxlO pfu (2); 
3 l.SxlO pfu (3). 
3 (H) LU-3 cell-free virus plus lxlO uninfected MRC-S cells 
(same nwnber pfu as in column (G). 
(I) HSV-1-infected MRC-S cells (l); HSV-1 DNA, 1 µg (2); 
HSV-2-infected MRC-S cells (3); HSV-2 DNA, 1 µg (4); 
pNSL22S DNA 0.2 µg (S). 
(Z) Dilutions of CMV AD169 DNA: 10 ng (l); 1 ng (2); 
100 pg (3); 10 pg (4). Hybridization on separate mem-
brarie under same conditions as samples in columns A-I. 
Control (ES): lxl03 uninfected MRC-S cells. CMV AD169 DNA (GS): 20 ng 
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TABLE 4 
Correlation of culture results with probe hybridization 
Clinical 
Specimen 
Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
to clinical urine specimens 
Culture Autoradiogram 
+ + 
+ 
Radioactivity of 
Spotted Membrane 
61 
70 
83 
58 
448 
51 
75 
76 
58 
95 
62 
80 
70 
67 
33 
Not Done 
II 
II 
" 
" 
II 
79 
( cpm) 
Table 4. 
Clinical 
Specimen 
Number 
22 
23 
(Cont'd) 
Culture 
Background (unspotted mem-
brane sample) 
Unlabelled pNSL225 DNA 
(1 µg in 0.5 ml lX SCC) 
Unlabelled pNSL225 DNA 
(1 µg spotted directly) 
Autoradiogram 
+ 
+ 
80 
Radioactivity of 
Spotted Membrane (cpm) 
Not Done 
" 
80 
133, 280 
29,051 
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passage of the original inoculated monolayer, was also negative with the 
probe. The second culture-positive specimen was from a patient with sus-
pected AIDS. The original culture was positive within 72 h and both the 
autoradiogram and scintillation counting fro~ the prepared urine specimen 
showed strong binding of the probe (Figure 14). The autoradiogram in 
Figure 14 also contains two of the culture-negative clinical specimens 
which fail to bind the probe. There are two faint areas of hybridiza-
tion which correspond to cells from monolayers infected with HSV-1 and 
HSV-2. This was the only experiment in which there was background hybrid-
ization with these two viruses. The RSV samples contained cells whereas 
the clinical specimens were cell-free. It may be that the processing of 
the membrane during this experiment was inadequate to remove cellular 
material which might nonspecifically bind the probe. In addition, a dif-
ferent cell type (MRHF) was inoculated with the viruses. Previously 
MRC-5 cells had been used. The possibility of probe binding to MR.HF 
cells should be investigated for any future experiments which require 
virus-infected cells. 
The procedure for processing the clinical specimens was a modi-
fication of that of Chou and Merigan (13). The salt concentration of 
the NaOH/NaCl solution used to disrupt the pelleted virions was lowered 
from 2M to 0.3M such that the final concentration of the specimen to be 
filtered would be equal to that of lX SSC (0.15 M NaCl). This change was 
instituted on the advice of the GeneScreen Plus manufacturer (New England 
Nuclear) to achieve optimal binding of DNA to the membrane. To check for 
adequate binding of DNA to the membrane 1 µg of unlabelled probe DNA was 
added to 0.5 ml lX SSC and filtered with the Minifold apparatus. Another 
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Figure 14. Direct hybridization of B fragment probe to patient 
urine specimens. The large spots in column A represent 
1 µg of unlabelled pNSL225 DNA either spotted directly 
(row 2) or placed in 0.5 ml lX SSC and filtered onto 
the membrane (row 1). Faint spots in row 3 of columns 
B and C are HSV-1 and HSV-2-infected ·MR.HF cells. The 
large spot in column C row 4 is the sample from the 
suspected AIDS patient. Two other culture-negative 
clinical samples were spotted in row 4 columns A and B 
but did not bind the probe. Exposure time 23 hours. 
1 
2 
3 
4 
A B · C 
84 
1 µg was spotted directly on the membrane. Both DNA samples hybridized 
to the probe equally (Figure 14). 
Biotin-Labelled Probe. The biotin-labelled probe was first hy-
bridized to a duplicate membrane corresponding to Figure 12. For both 
stock AD169 and the three clinical isolates, 105 infected cells could be 
visualized. For the AD169 and LU-1 samples, 104 infected cells also pro-
duced an easily visible color reaction. The corresponding dilutions of 
LU-2 and LU-3 were very much fainter. All other dilutions were negative 
as was the control containing 106 uninfected cells. The CMV and pNSL225 
DNA controls were positive, and HSV-1 and HSV-2 DNA spots were negative. 
These results suggested a 10-100 fold lower degree of sensitivity for 
the biotin probe over the corresponding radiolabelled probe. 
The next membrane to which the biotin probe was hybridized was a 
duplicate of that in Figure 13. The probe failed to detect any of the 
virus or virus plus cells samples. Probe and CMV DNA were of the same 
color intensity as in the previous experiment. There was no hybridiza-
tion to HSV-1 or HSV-2 DNA nor to the control cells. The total lack of 
color reaction for any of the virus samples was unexpected, since all 
samples were readily detected with the radiolabelled probe. Both mem-
branes were inoculated at the same time and prehybridized using the Gene-
Screen protocol. The same biotin probe sample from the previous experi-
ment was reused for this membrane, which is in agreement with the_manu-
facturer's recommendations. The positive controls seemed to be valid. 
From this experiment it would appear that the biotin probe is even more 
than 100-fold less sensitive than the radiolabelled probe. It should be 
noted, however, that the amount of CMV DNA present in heavily infected 
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cells far exceeds the amount of DNA which would be released from cell-
free virus stocks. Thus the amount of DNA on the membrane in the pre-
vious experiment is much greater than that in this experiment. The dif-
ficulty in interpretation arises from the direct comparison of the 
biotin and radiolabelled probes in this experiment. 
The biotin probe was next hybridized to the same dilutions of 
naked CMV DNA seen in Figure 13. A visible color reaction was present 
for the 100 pg but not for the 10 pg dilution. This represents more 
than a 10-fold difference in sensitivity, since it would appear from 
the autoradiogram that less than 10 pg of DNA might be detected, and the 
100 pg spot on the biotin probe membrane was very faint. 
The biotin probe was hybridized to the first 11 of the 23 clini-
cal urine specimens. Variable color reactions occurred in the inocu-
lated areas with no correlation to the culture or autoradiographic re-
sults. The specimen from the suspected AIDS patient showed the same 
amount of color development as several culture-negative specimens. Some 
of the other culture-negative specimens had background color produced 
by substances present in the urine sediment. 
Only 20% of each prepared clinical urine specimen was actually 
spotted on a membrane for hybridization to the biotin probes. Sixty 
percent of the specimen was filtered with the Minifold onto a mem-
brane for hybridization to the 32P-labelled probe. In Figure 14 it 
can be seen that the culture-positive specimen from the suspected 
AIDS patient was positive by autoradiography, and that other culture 
negative specimens were negative by this technique as well. Com-
parison of the hybridization of the biotin and 32P-labelled probes 
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with culture results of these clinical specimens suggests that the bio-
32 tin-labelled probe binds non-specifically, while the P-labelled probe 
hybridization correlates with the culture results. 
Another experiment was performed to try to quantitate the biotin 
probe sensitivity with stock virus dilutions. Samples of AD169, LU-1, 
LU-2 and LU-3 stock cell-free virus were placed in the Minifold filtra-
tion apparatus and applied to a GeneScreen Plus membrane. The corre-
sponding pfu for each dilution are listed in Table 5. It would appear 
5 that the probe can detect 1 x 10 pfu. This can be compared to Fig-
3 
ure 13 where the radiolabelled probe detected 1 x 10 pfu of LU-2. To 
make sure that the membrane would bind DNA in solution during the fil-
tration process, 1 µl of pNSL225 DNA was diluted with 0.5 ml lX SSC and 
placed in a Minifold well. Another 1 µl of the pNSL225 DNA was spotted 
directly onto the membrane. Both samples appeared equally clearly on 
the membrane after hybridization. This experiment again suggests at 
least a 100-fold difference in sensitivity between the biotin and 32P-
labelled probes. 
No firm conclusion concerning the relative sensitivity of the 
biotin probe should be made, however, since there were some technical 
variations and difficulties in following the manufacturer's protocol. 
The protocol was revised by Enzo-Biochem for the amount of probe DNA re-
quired for hybridization. There were also changes made by the manu-
facturer in the hybridization method, which may account for some of the 
variability of the results. For example the final membrane washing 
with 2X SSC after color development was added to the original protocol. 
This step reduces the background color. In addition two different 
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TABLE 5 
Quantitation of biotin probe sensitivity 
Virus pfu Color DeveloEment 
AD169 1 x 106 ++ 
1 x 105 + 
1 x 104 
1 x 103 
LU-1 1. 8 x 10 6 ++ 
1.8 x 10 5 + 
1.8 x 10 4 
1. 8 x 10 3 
LU-2 1.5 x 105 + 
-
1.5 x 104 
1.5 x 103 
1.5 x 102 
LU-3 1 x 105 + 
1 x 104 
1 x 103 
1 x 102 
Control pNSL225 DNA (1 µg) ++++ 
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methods were used for retrieving the probe following nick translation. 
The original probe samples were placed on a 3.5 ml Sephadex G-50 column 
and fractions were collected. Since 3H-labelled ATP was added to the 
nick translation reaction in addition to cold ATP, the incorporated 
label could be used to select the fractions containing the probe. 
Another method was the use of a 1 ml Sephadex G-50 spin column 
(Enzo-Biochem protocol). Theoretically the 50 µl nick translation vol-
ume should be recovered in approximately equal volume after centrifuga-
tion in an Eppendorf tube at the tip of the Sephadex column. The actual 
volume which was collected in 4 different nick translation reactions 
varied from 200-500 µl. 3 To check that the H-labelled probe was sep-
arated from unincorporated nucleotides, one of the probe samples was 
placed on a 3.5 ml column and fractions were collected as before. There 
was only one peak of radioactivity, which occurred right behind the void 
volume; therefore, the probe had been separated but was present in too 
large a volume. The samples were each ethanol precipitated; recounting 
indicated that the probe was concentrated. It may be, however, that 
more probe was lost during the purification steps of the spin column 
technique than during purification on the 3.5 ml Sephadex column. A 
loss of biotinylated probe would have reduced the apparent sensitivity 
of the hybridizations in the last experiment described above. 
DISCUSSION 
Tissue culture has been the standard method for virus isolation 
and identification in the laboratory. The method is both specific and 
sensitive in that a single plaque-forming unit of virus can be amplified 
from the original inoculum to produce visible CPE. However, replication 
of many viruses is very slow in tissue culture; the method is expensive, 
and not all viruses can be easily propagated in cell types coIIUilonly 
used for virus screening. 
Recently the need for more rapid diagnostic tests for viral in-
fections has increased with the introduction of antiviral chemotherapy. 
Many of the currently approved drugs have very narrow spectra of anti-
viral activity (53), which makes identification of the etiologic agent 
important for treatment of each individual viral disease. In addition 
monitoring of the progress of treatment requires rapid laboratory re-
sults (13,81,105,118) •. Rapid identification of viral disease can also 
curtail the need for extensive diagnostic testing and aid in the epidemi-
ologic control of virus dissemination (105). 
The use of nucleic acid probes shows promise as a technique for 
rapid viral detection and identification. Richman et al. (105) were 
4 
able to detect 1 pg of purified HSV DNA or 10 pfu of cell-free virus 
with several HSV probes. Herpes simplex type specificity was achieved 
with probes carrying fragments from the junction region of the genome 
(105) or by increasing the stringency of the hybridization conditions 
(122). Similar probes developed for the detection of EBV (3,7) were 
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able to detect 2-5 pg of DNA. Hybridization methods for identification 
of adenovirus (134) and human papilloma virus (16) have been recently 
reported. Probes for RNA viruses have also been developed. Type-spe-
cific probes for rotaviruses were shown to hybridize to 8 pg of homol-
ogous double-stranded RNA (33). A copy DNA probe containing the rep-
licase gene of coxsackievirus B3 could detect other enteroviruses in 
tissue culture inoculated with stool specimens (63). Hybridization in 
culture occurred with coxsackieviruses A and B, echovirus, and polio-
virus. The sensitivity, however, was not sufficient to detect these 
viruses directly in the original specimen. 
The slow growth of CMV in routine laboratory tissue culture has 
prompted a search for faster methods for detecting this virus, and DNA-
DNA hybridization has been one line of investigation (13,81,118). The 
goal of this project has been the development of a DNA probe for rapid 
detection and identification of CMV. Several steps were required in 
the development process: 1) isolation of CMV DNA from strain AD169; 2) 
cloning of BamHI restriction endonuclease fragments of the viral DNA; 
3) selection and identification of an appropriate cloned fragment for a 
probe, and 4) determination of the sensitivity and specificity of the 
radiolabelled and biotin-labelled probe for CMV. 
Cytomegalovirus AD169 is a well-characterized laboratory strain 
for which there is a restriction map available (49). This strai~ was 
used as a source of viral DNA, because the virions are released extra-
cellularly. Typical wild-type CMV strains remain highly cell-associated. 
The extracellular virions provide a source of viral DNA which is free of 
cellular DNA. Cellular debris can be removed by low-speed centrifuga-
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tion before the virus particles are pelleted from the supernatant fluid. 
The method of DNA isolation which finally allowed the production of 
enough DNA for cloning did not require further purification of the pel-
leted virus (76). The virions were lysed directly after resuspension 
in a small amount of buffer. The lysate was extracted twice with or-
ganic solvents and then dialyzed. No gradient was required at any 
point during the procedure, and DNA suitable for restriction enzyme 
analysis was obtained. The BamHI restriction endonuclease digestion 
pattern (Figure 9) of the isolated CMV DNA matches that published by 
Huang et al. (60) for strain AD169. Furthermore the lack of a fluor-
escent background suggests that the CMV DNA is chemically pure and not 
contaminated with other DNA species. 
The plasmid vector pBR322 was chosen for its ready availability 
and well-characterized restriction map (18,82). BamHI was chosen as 
the enzyme to produce DNA fragments for cloning, because inactivation 
of tetracycline resistance by insertion at the BamHI site in pBR322 pro-
vides a consistent screening marker for recombinant plasmids. HindIII 
has been used by others (75) to produce cloned CMV fragments. The ad-
vantage of this enzyme is that it cuts the DNA into fewer fragments than 
does BamHI, and the largest -fragments of the .HindIII digest are consid-
erably larger than the largest BamHI fragments. The disadvantage of 
HindIII is that insertion at the HindIII site in pBR322 does not ~on­
sistently inactivate tetracycline resistance. Cytomegalovirus AD169 
DNA fragments have been cloned into the EcoRI site in pACYC184 (129). 
EcoRI also has fewer restriction sites in the CMV genome, but there is 
no selection marker for insertion at the EcoRI site in pBR322. The 
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largest EcoRI fragments are not much larger than the largest BamHI frag-
ments; therefore, there seemed to be no advantage to using the EcoRI/ 
pACYC184 system. Insertion at the Pstl site inactivates the ampicillin 
resistance marker of pBR322, but two of the largest restriction frag-
ments produced from CMV AD169 DNA are found in the junction region of 
the genome. These fragments are present in only 0.25 M quantity in the 
total CMV DNA digest, which means that only one-fourth of the viral 
genomes contain the intact fragment sequence. This enzyme also pro-
duces significantly smaller fragments than does BamHI. The enzyme which 
produces the largest and fewest restriction fragments in CMV AD169' DNA 
is Xbal, but there is no restriction site for this enzyme in pBR322. 
Thus, considering all of the commonly used enzymes and vectors, BamHI 
with pBR322 seemed to be the most convenient combination to use for 
cloning. 
A cloned fragment to be used as a probe should contain DNA se-
quences which are connnon to all HCMV strains and which are present in 
all con~igurations of the genome. There were, therefore, two types of 
recombinant plasmids of interest. First, a plasmid with a large single 
insert preferably the A or B fragment of the BamHI digest was sought 
for its long unique sequence. Second, the U fragment was considered 
desirable for its 2 molar concentration in the total CMV AD169 genome. 
Two plasmids (pNSL215 and pNSL225) were selected for further study, be-
cause they had large single inserts. Both plasmids turned out to carry 
the B fragment in the same orientation (Figure 7). This identification 
was established by both restriction endonuclease digestion patterns of 
each plasmid insert and hybridization of the radiolabelled recombinant 
plasmid with restriction endonuclease digests of total CMV AD169 DNA 
(Figures 5,6 and 9). 
Two other cloned plasmids {pNSL45 and pNSL186) were chosen for 
analysis, because their single inserts migrated with the band of the 
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CMV BamllI digest which contained the U fragment. Both plasmid inserts 
were subsequently confirmed to be the U fragment. Again restriction 
endonuclease digestion patterns of the inserts and hybridization of the 
32P-labelled plasmid with total CMV digests were the methods used to 
establish the identity of the cloned fragments (Figures 8 and 10). 
Based on recent reports of variability among CMV strains in the 
repeat regions of the genome (75,143) and sequences in the repeats, 
which were at least partially homologous to cellular DNA sequences (85), 
it was decided that the U fragment in the I~ might not be desirable for 
a probe. The B fragment is found in the UL segment of the genome in a 
region that has not yet been reported to be either variable among CMV 
strains or homologous to cellular DNA (15,86,94,119). This fragment 
was, therefore, chosen for all subsequent experiments. 
It was obvious from the fragment identification experiments, that 
the probe containing the B fragment hybridized to CMV strain AD169 DNA 
(Figure 9). This probe was then tested for its ability to hybridize 
with DNA from laboratory strains of HSV-1 (strain F), HSV-2 (strain 333) 
and EBV (strain B95-8). The Southern blots showed no cross-react_ivity 
of the probe with any segment of these DNA digests (Figure 11), al~ 
though, as previously mentioned, there was only about half as much EBV 
DNA as CMV DNA present on the filter. The only other human herpesvirus 
which would be of clinical significance is VZV, but unfortunately no 
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DNA from that virus was available for testing. We can conclude from 
these experiments that the CMV B fragment probe shows no detectable hy-
bridization with DNA from these strains of HSV-1, HSV-2 and EBV. It 
still remains possible that the DNA from other isolates of these viruses 
or from VZV could cross-react with the probe. However, other reports 
(59,94) suggest it is unlikely that llllder the conditions of hybridiza-
tion used in these experiments, there would be su~ficient homology be-
tween the genomes of these viruses and CMV to alter the specificity of 
the probe. In converse experiments, Richman et al. (105) demonstrated 
that RSV probes did not hybridize with CMV- or VZV-infected cells. 
Since the probe was a construct containing a unique sequence DNA 
fragment of CMV strain AD169, it was necessary to demonstrate that it 
could hybridize with other strains of CMV. The three clinical isolates 
which were initially tested were obtained from specimens submitted to 
the clinical virology laboratory for culture. Repeated passage of in-
fected monolayers eventually led to the production of 100% CPE with 
release of infectious virus into the culture supernatant fluid. The 
probe could then be used to detect both cell-free virus and virus-in-
fected cells (Figures 12 and 13). The probe hybridized very strongly to 
these isolates under either cell-free or infected-cell conditions. 
These results do not prove conclusively that the probe can detect all 
human strains of CMV, but there appears to be sufficient homology re-
ported among HCMV strains (58,142) to suggest that the probe should be 
able to detect all clinical isolates. 
Quantitative experiments were designed to determine the amount 
of CMV DNA and the number of plaque-forming llllits of intact virus re-
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quired to produce a visible reaction by autoradiography. The 10 pg sam-
ple of CMV AD169 DNA could easily be seen on an autoradiogram after 20 
hours of exposure (Figure 13). 4 This represents about 4 x 10 genomes 
of CMV. The degree of sensitivity in the picogram range is in agree-
ment with that reported by Chou and Merigan (13). No purified DNA from 
strains of CMV other than AD169 was available for testing; therefore, 
the sensitivity of the probe could differ among CMV strains, if there 
were any variability of the sequences homologous to the AD169 BamHI 
fragment. The evidence from the experiment using dilutions of cell-
free virus from the clinical strains LU-1, LU-2 and LU-3 (Figure 13), 
however, suggests that the B fragment probe is probably nearly as sen-
sitive for strains other than AD169. The intensity of hybridization of 
the probe with each of these clinical strains correlates with the num-
ber of pfu spotted on the membrane. For example the three dilutions of 
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strain LU-1 represent 1.8 x 10 , 4.5 x 10 and 4.5 x 10 pfu respec-
tively, and the intensity of the spots on the autoradiogram decreases 
with each dilution. The lowest number of pfu detected with the probe 
3 is 1 x 10 pfu represented by the highest dilution of strain LU-2. This 
degree of sensitivity is similar to that reported by others (13). 
The amount of CMV DNA which is actually present for each dilution 
in Figure 13 is difficult to determine, since the ratio of pfu to viral 
particles is very low for CMV and may well vary from one preparation of 
virus to another. The many noninfectious particles may contribute DNA 
which will increase the intensity of probe hybridization. A correla-
tion between pfu and probe sensitivity may, therefore, be misleading 
without electron microscopy to show the number of viral particles con-
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taining DNA. In addition there may be many virions containing defec-
tive DNA, which might include a deletion of some or all of the B frag-
ment sequences. The evidence presented here, however, generally in-
dicates that the radiolabelled probe is likely to detect at least the 
majority of HCMV strains with a reasonably high degree of sensitivity. 
32 In comparison with the P-labelled probe the sensitivity of the 
biotinylated probe was found to be at least 100-fold lower when the 
nick translation was performed according to the protocol published by 
Enzo-Biochem. Dilutions of CMV AD169 DNA could barely be visualized at 
the 100 pg level whereas the radiolabelled probe was easily able to 
produce a dark spot on the autoradiogram with 10 pg of DNA. Equivalent 
membranes carrying dilutions of stock virus sainples (Figure 13 and 
Table 5) also showed the much lower sensitivity of the biotin probe as 
32 
compared to the P-labelled probe. 
The next step was to hybridize the radiolabelled probe to actual 
clinical specimens to see if the probe could directly detect CMV before 
inoculation of tissue culture. Samples from urines sent to the clinical 
laboratory for CMV culture were processed for autoradiography. A mul-
tiple filtration apparatus (Schleicher and Schuell Minifold) was used 
so that all of the pelleted sample could be spotted on the membrane. 
The results of the hybridizations with the clinical specimens show that 
virus present in urine can be pelleted and detected directly with the 
radiolabelled probe (Figure 14), but quantitative levels of detection 
have not been determined. One specimen, which was positive by both cul-
ture and autoradiography was from a suspected AIDS patient, who appeared 
to be excreting a high titer of virus. This was indicated by the fact 
97 
that CPE was present within 72 hours after culture inoculation. The 
one specimen which was culture-positive but negative by autoradiography 
and scintillation counting had a very low viral titer. The initial cul-
ture was negative and a blind passage became positive with very few in-
fectious foci after several weeks of incubation. All other urine spec-
imens from this patient have been culture-negative for CMV. The re-
maining clinical specimens (21 out of 23) tested were culture-negative 
and showed no hybridization with the probe. 
With only two known culture-positive clinical specimens available 
the probe has not been adequately tested for direct detection of CMV 
in clinical samples. The data so far only indicate that the probe is 
capable of detecting clinical strains of CMV when the virus is present 
in quantities sufficient to produce CPE in the initial culture. 
Other investigators have successfully used different _CMV probes 
for direct detection of the virus in clinical specimens. Chou and 
32 Merigan (13) used the cloned CMV AD169 EcoRI 0 fragment as a P-la-
belled probe for hybridization to urine specimens and were able to de-
tect virus at a titer of 103 or higher in the original sample. They 
reported no false-positive results. Spector et al. (118) hybridized 
32 P-labelled probes carrying the CMV AD169 EcoRI B and D fragments to 
huffy coat specimens from bone-marrow transplant patients. They re-
ported that the DNA-hybridization technique was more sensitive than 
tissue culture for detecting CMV infection in these patients. Marlowe 
et al. (81) could demonstrate the presence of CMV in 19 of 20 culture-
positive urines as well as three lung biopsy specimens. 
belled probe contained cloned fragments of CMV Towne DNA. 
32 Their P-la-
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The use of 32P for detection of probe hybridization can provide 
both sensitivity and rapid results. Low levels of hybridization can be 
visualized by holding autoradiograms for longer periods of time. Sein-
tillation spectrometry can be used in place of autoradiography to de-
crease the time required for testing (13). The disadvantages associated 
with the use of 32P are the short half-life (14 days) and the high 
radiation energy hazard of the isotope. 
By contrast the main advantages of the biotinylated probe are 
the lack of radioactivity and the stability of the probe. According 
to the manufacturer the biotin label is stable for at least a year. The 
Enzo-Biochem nick translation procedure, however, also calls for the in-
3 
corporation of a small amount of H-labelled ATP as well as cold ATP. 
The radioactivity is used as a tracer to facilitate the recovery of the 
probe from the unincorporated nucleotides on a Sephadex G-50 column. 
Presumably the radiolabel can be eliminated, if either a spin column or 
ethanol precipitation method is used for probe recovery. The Enzo-
Biochem protocol unfortunately does not address the problem of the un-
desirability of the tritium label. 
In addition to lower sensitivity non-specific binding in the 
presence of cells or clinical material made the biotinylated probe un-
suitable for direct detection of the virus. Technical difficulties, 
however, may be responsible for the unsatisfactory results with this 
reagent. The conclusion drawn from the experiments for this project is 
that the 32P-labelled probe is at the moment much better than the bio-
tinylated probe for detection of CMV. 
There are recent reports, however, which suggest that modifica-
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tions in the biotin-labelling procedure can increase the sensitivity of 
these probes. Leary et al. (78) used alkaline phosphatase instead of 
hrp for visualization of probe hybridization. In an homologous plasmid 
reaction 3.1 pg of DNA could be detected. Richman et al. (105) used 
this modification and were able to detect 1 pg of HSV DNA, a level of 
32 
sensitivity which is equivalent to that of P-labelled probes. The 
biotinylated probe for EBV constructed by Sixbey et al. (112) ·was de-
tected with fluoro&:ein-isothiocyanate- labelled avidin and was found to 
be more sensitive than a comparable probe labelled with 32P. 
Directions for Future Research. The evidence so far suggests 
that the CMV BamHI B fragment probe will dete~t the majority of HCMV 
strains, but further testing will be required to demonstrate that all 
isolates from clinical specimens will hybridize to the probe. For ex-
ample, there is one strain of CMV, strain Colburn, which was originally 
isolated from a patient, but which has been shown to be more closely re-
lated to simian strains of CMV than HCMV (61,67). It is also known 
that simian strains can be propagated in human cell culture (61,132), 
although there are no reports describing human infections with these 
viruses. The B fragment probe from CMV AD169 needs to be tested. against 
strain Colburn and other simian strains in the event that in the future 
such strains of CMV are found to produce human disease. 
The clinical usefulness of the probe has not yet been demon-
strated~ Titering of specimens needs to be performed at the time of 
initial inoculation to determine the number of pfu originally present. 
The sensitivity of the probe for direct detection of CMV in patient 
specimens can then be correlated quantitatively with the culture results. 
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An additional clinical application of the probe would be the· 
identification of CMV in laboratory tissue culture where the titer of 
the original specimen was too low to detect directly. Presently iden-
tification of CMV is based on the rate of appearance of typical CPE and 
the types of cells in which the virus will grow. Immunological methods 
of identification are often inconclusive (124). In situ hybridization 
with either the radiolabelled or biotinylated probe could be performed 
at specific times after inoculation of replicate tissue culture mono-
layers. If this technique were sufficiently sensitive, a positive re-
action could identify infection with CMV before the appearance of CPE. 
Positive results would, therefore, be available earlier, and these cul-
tures would require no further laboratory work. 
The most clinically significant aspect of nucleic acid hybrid-
ization techniques for detection of viruses is the potential for ob-
taining rapid laboratory results. The method used for the development 
of the probe during this project allows detection and identification of 
CMV in 48 h (7). Chou and Merigan (13) referred to the same hybridiza-
tion protocol but claimed to have results in 24 h. This means the 
period of hybridization would have to be reduced to less than 24 h. 
Other reports (81,118), however, support the claim that reliable re-
sults can be obtained in 24 h. 
Biotin-labelled probes can shorten the time even more, because a 
high concentration of probe can be used for hybridization without 
raising the level of non-specific binding (78). Richman et al. (105) 
reported that their procedure for RSV could be performed in 5 h. Future 
experiments to demonstrate the clinical application of the CMV probe 
Wl 
developed for this project should address the question of the rapidity 
with which the probe can detect and identify the virus. Forty-eight 
hours for detection of CMV as performed during this project is in most 
cases faster than tissue culture, and the specificity of the probe pro-
vides more certain identification of CMV than the appearance of the CPE. 
The prospect of shortening the time required for complete identification 
of this virus adds to the potential clinical usefulness of the probe. 
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